DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

20230704132271

Årsredovisning för

Eli Lilly Sweden AB

556135-1171

Räkenskapsåret
2022-01-01 - 2022-12-31

Innehållsförteckning: **Sida**

Förvaltningsberättelse	1-4
Resultaträkning	5
Balansräkning	6-7
Kassaflödesanalys	8
Rapport över förändringar i Eget kapital	9
Noter	10-15
Underskrifter	16

Fastställelseintyg

Undertecknad styrelseledamot i Eli Lilly Sweden AB intygar härmed dels att denna kopia av årsredovisningen överensstämmer med originalet, dels att resultat- och balansräkningen fastställts på årsstämma 28-06-2023 stämman beslutade också att godkänna styrelsens förslag till resultatdisposition.

Solna 28-06-2023

DocuSigned by:
Damir Mörk
D4E40845441F47F...

Damir Zaufavec Mörk

Damir Mörk

DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

Förvaltningsberättelse

Styrelsen och verkställande direktören för Eli Lilly Sweden AB, 556135-1171, med säte i Stockholm län, Stockholm kommun, avger härmed följande årsredovisning för räkenskapsåret 2022-01-01 - 2022-12-31.

Allmänt om verksamheten

Eli Lilly och Company upptäcker, utvecklar, tillverkar och marknadsför produkter inom ett enda affärssegment - humanläkemedel. Vårt syfte är att förena vård med upptäckt för att skapa läkemedel som gör livet bättre för människor runt om i världen. De flesta av de produkter vi säljer idag upptäcktes eller utvecklades av våra egna forskare och vår långsiktiga framgång beror på vår förmåga att ständigt upptäcka eller förvärva, utveckla och kommersialisera innovativa nya läkemedel. Våra produkter säljs i cirka 120 länder och globalt hjälper Lilly 51 miljoner människor med mediciner och att hantera allvarliga och utmanande sjukdomar så som dibabetes , cancer, migrän och autoimmuna tillstånd.

Våra prioriterade terapiområden inkluderar diabetes, onkologi, dermatologi, reumatologi, neurologi och immunologi.

Ägarförhållanden

Samtliga aktier ägs - och har under hela räkenskapsåret ägts - av Lilly Holdings B.V. (Nederländerna).

Utveckling av företagets verksamhet, resultat och ställning

Belopp i kkr	*2022-12-31*	*2021-12-31*	*2020-12-31*	*2019-12-31*	*2018-12-31*
Nettoomsättning	454 810	503 108	501 384	534 106	530 786
Resultat efter finansiella poster	22 881	20 178	22 635	14 644	22 229
Balansomslutning	168 632	142 414	193 776	178 955	184 335
Soliditet %	48	44	47	20	46
Avkastning på eget kapital %	28	32	25	20	20
Medelantal anställda	47	46	52	50	69

Definitioner: se not 1

Väsentliga händelser under räkenskapsåret

Under 2022 fortsatte Lillys produktportfölj att växa över flera viktiga terapeutiska områden i det nordeuropeiska navet. I Sverige förekom produktgodkännanden i våra onkologi- och diabetesportföljer.

År 2022 hade den globala covid-19-pandemin återigen betydande inverkan på Lillys förmåga att bedriva affärer genom personliga kanaler. Under hela denna period har företaget varit fokuserat på att upprätthålla en pålitlig försörjning av våra läkemedel; minska belastningen på det medicinska systemet; tillhandahålla effektiva behandlingar för covid-19; och skydda våra anställdas hälsa, säkerhet och välbefinnande. Under de senaste 12 månaderna har vi upplevt både en paus och återupptagande av personliga interaktioner i takt med de riktlinjer som införts över hela landet enligt sjukdomens toppar och vågor. I slutet av året var den personliga interaktionen återställd efter en betydande period av distansarbete på grund av covid-19.

Ovanliga saker
Under 2022 påverkades inte de finasiella rapporterna av några väsentliga ovanliga händelser.

Förväntad framtida utveckling samt väsentliga risker och osäkerhetsfaktorer

Vår interna läkemedelsforskning fokuserar främst på områdena diabetes, onkologi, immunologi,

DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

20230704322772

neurodegeneration och smärta. Förutom att upptäcka och utveckla nya läkemedel, försöker vi utöka värdet av befintliga produkter genom nya användningsområden och formuleringar för att ge ytterligare värde till patienterna.

Hitills har situationen i Ukraina/Ryssland inte påverkat Eli Lilly Sweden AB. Globalt har Lilly stoppat alla investeringar, marknadsföringsaktiviteter och nya kliniska prövningar i Ryssland, samt exporten av icke-essentiella läkemedel till det landet. Vår ryska verksamhet fokuserar bara nu på att se till att människor som lider av sjukdomar som cancer och diabetes fortsätter att få de Lilly läkemedel de behöver.

Allmänna risker

Eli Lillys viktigaste operativa risker är vår förmåga att få tillgång till nya läkemedel, att skydda våra IP-rättigheter och arbeta framgångsrikt med våra nyckelintressenter.

Hälsa, säkerhet och miljö

Lilly har ett starkt fokus på att främja en hälsosam miljö, upprätthålla en säker arbetsplats och arbeta ansvarsfullt, med det globala HSE-programmet som hanteras under en enhetlig styrningsstruktur.

Vi arbetar under ett antal principbaserade policyuttalanden som implementeras genom globala rutiner som beskriver våra grundläggande principer och förväntningar och genom globala standarder som beskriver mer detaljerade, granskbara krav.

På Lilly mäter vi både ledande och eftersläpande indikatorer när vi bedömer vår övergripande säkerhetsprestanda. Vi har funnit att spårning av ledande eller prediktiva indikatorer, såsom ergonomiska risker, säkerhetskulturpoäng och prekursorer för livsförändrande och dödsfallsrisker, i hög grad bidrar till vårt företags säkerhetsprestanda. Genom att använda dessa indikatorer i kombination med eftersläpande indikatorer, såsom vår skadefrekvens, kan vi måla upp en heltäckande bild av de områden som mest påverkar de anställdas säkerhet i Lilly. Detta tillvägagångssätt gör att vi både kan påverka förändringar där det behövs och spåra våra säkerhetsframsteg på konkreta sätt över tid.

Lilly etablerade nya säkerhetsmått kopplade till våra säkerhetsprioriteringar och förbättrad säkerhetskultur. Våra prioriteringar inkluderar utveckling av säkerhetsledarskapsförmåga, minskning av våra viktigaste risker som kan få livsförändrande eller dödliga konsekvenser och hantering av affärskontinuitetsrisker, inklusive de som är förknippade med processsäkerhetshantering. Dessutom fastställde vi ett nytt säkerhetsmål att uppnå noll allvarliga skador med fokus på ständiga förbättringar. År 2022 var vår frekvens av allvarliga skador 0,51 skador per 500 anställda, vilket motsvarar en ökning jämfört med 2021 års frekvens på 0,41. En del av ökningen av allvarliga skador från 2021 till 2022 tillskrivs sannolikt mer på plats och fältbaserad aktivitet efter pandemin. Vi strävar efter att uppnå ständiga förbättringar i denna prestation när vi arbetar för att uppnå en skadefri arbetsplats.

Vårt syfte, att göra livet bättre, inkluderar att skydda och bevara världen vi lever i. Att tillverka läkemedel kräver användning av värdefulla resurser inklusive energi, vatten och råvaror. Vi är fast beslutna att minska vårt miljöavtryck över våra produkters och vår leveranskedjas livscykler. Lilly fastställde nya miljömål inklusive för klimat, avfall och vatten som löper fram till 2030; dessa inkluderar mål att bli koldioxidneutrala i vår egen verksamhet.

Hållbarhetsrapport

Lilly är fortsatt engagerad i att förbättra vår miljöpåverkan under våra produktlivscykler och försörjningskedjan och har satt upp nya mål för att ytterligare minska utsläpp och avfall och att aktivt genomföra vattenhanteringsplaner för alla Lilly-anläggningar i vattenstressiga områden.

Vi har satt upp nya aggressiva mål och har ett etablerat globalt energihanteringsprogram. Vårt mål för 2030 är att 100% av inköpt el ska komma från förnybara källor, förbättra spårning och rapportering av utsläpp från hela vår värdekedja och uppnå koldioxidneutralitet i vår verksamhet.

Lilly förstår fullständigt att det mest effektiva sättet att minska avfallet är att inte skapa det, och vi är

DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

fast beslutna att minimera avfallet för att spara energi och resurser och minska deponeringsutrymmet. Företaget har som mål att noll avfall ska deponeras, allt plastavfall återanvänds för fördelaktig användning och att hållbara designprinciper införlivas i produkt- och förpackningsdesignprocesser.

Mångfald och inkludering av anställda

Att stärka en mångfaldig arbetsstyrka fortsätter att vara ett viktigt fokusområde för Lilly, och vi är engagerade i att skapa och upprätthålla en öppen, inkluderande och mångfaldig miljö, där alla anställda känner sig värderade, respekterade och hörda. Att omfamna mångfald innebär att förstå, respektera och värdera skillnader, inklusive men inte begränsat till ras, färg, religion, kön, sexuell läggning, könsidentitet, nationellt ursprung, skyddad veteranstatus, funktionshinder eller annan juridiskt skyddad status.

För att främja en stark tillhörighetskultur finns det fem anställdas resursgrupper som är aktivt engagerade i den nordeuropeiska navet, inklusive Gender Inclusion Network som arbetar för att ta bort hinder som hindrar kvinnor och män på Lilly från att uppnå sin fulla potential; Generation-Lilly vars syfte är att främja och omfamna en multigenerationskultur; ENABLE som har som mål att skapa en handikappsäker kultur; HBT+allierade som främjar lika upplevelse, behandling och säkerhet för lesbiska, homosexuella, bi- och transpersoner; och embRACE, en personalresursgrupp, med syftet att skapa en miljö där färgade personer får möjlighet att vara sina autentiska jag och en kultur där vi hyllar olikheter.

När vi sätter upp ambitiösa mål och fortsätter att mäta våra framsteg inom DE&I har vi sett en positiv trend i antalet kvinnor i ledarroller. Vi ökar från 42 % 2018 till 49 % 2022 och 33 % (5 av 15 medlemmar) av verkställande kommittén är kvinnor. 51 % av vår totala globala arbetsstyrka.

Välbefinnande

Vi vill att vårt företag ska vara en plats där våra anställda har meningsfullt arbete, bygger framgångsrika karriärer och gör viktiga bidrag till samhället, och medan pandemin har tvingat alla att arbeta på nya och olika sätt är företaget engagerat i att stödja alla anställda när de anpassa sig till både befintliga och nya sätt att arbeta.

För att stödja medarbetarnas välbefinnande fanns resurser för mental hälsa, inklusive användningen av affiliatebaserade förstahjälpare i landet, och den globala webbplatsen för välbefinnanderesurser med on-demand webbseminarier, levande träningslektioner och motståndsbyggande aktiviteter fortsätter. att vara tillgänglig för anställda i hela företaget.

Etik, efterlevnad och styrning

Lilly fortsätter att närma sig vårt företags verksamhet med en djup grund i våra grundläggande värderingar av integritet, excellens och respekt för människor. Det finns ett etablerat etikprogram som sträcker sig över en robust uppsättning policyer och förfaranden, vår uppförandekod (känd som The Red Book), personalutbildning och HR-prestations- och efterlevnadshanteringssystem.

Företaget har flera mekanismer för att rapportera och upptäcka eventuella överträdelser av överensstämmelse, inklusive obligatorisk rapportering av anställda om kända eller misstänkta överträdelser, ett robust övervakningsprogram för intern efterlevnad, intern företagsrevision och där det är tillåtet enligt lag, en anonym anställd som rapporterar hotline.

Vi driver regelbundet uppdateringar och utbildning som stöder ett bedömningsbaserat tillvägagångssätt för beslutsfattande, som syftar till att hjälpa anställda när de navigerar över en alltmer komplex intern och extern affärsmiljö.

Transparans och Upplysningsplikt

För att bygga upp och upprätthålla förtroendet hos dem vi tjänar fortsätter Lilly att stödja olika insynsinsatser på global nivå. Företaget uppmuntrar öppet rapportering av finansiella interaktioner med sjukvårdspersonal (HCP) och vårdorganisationer (HCO), och tillsammans med öppenhet i

betalningsrapporteringen stöder det aktivt HCP-ersättning för kontrakterat arbete till en rättvis marknadsränta. Rapporten Lilly HCP och HCO Transfer of Value 2020 publiceras årligen enligt riktlinjerna på webbplatsen Collaboration Database på Läkemedelsbolagen Industri Förening (LIF).

20230704322773

Källor:

www.Lilly.com

ELI LILLY AND COMPANY_10K_2022_V1 (ctfassets.net)

https://esg.lilly.com/social#tab-control-tab3

Lilly Ukraine Support | Eli Lilly and Company

Förslag till disposition av företagets vinst eller förlust

	Belopp i kr
Styrelsen föreslår att till förfogande stående medel:	
balanserat resultat	21 011 866
årets resultat	17 732 237
Totalt	38 744 103
disponeras för	
utdelning, [350 000 st * 85,71 kr]	30 000 000
balanseras i ny räkning	8 744 103
Summa	38 744 103

Vad beträffar resultat och ställning i övrigt hänvisas till efterföljande resultat- och balansräkning med tillhörande noter.

Resultaträkning

Belopp i kkr	*Not*	*2022-01-01-2022-12-31*	*2021-01-01-2021-12-31*
Nettoomsättning	*2*	454 810	503 108
Övriga rörelseintäkter		21 433	19 821
		476 243	522 929
Rörelsens kostnader			
Handelsvaror		-333 884	-391 337
Personalkostnader	*3*	-79 187	-69 558
Övriga externa kostnader	*4,5*	-40 219	-41 672
Av/nedskrivningar av materiella och immateriella anläggningstillgångar	*9,10*	-172	-164
Rörelseresultat		22 781	20 198
Resultat från finansiella poster			
Ränteintäkter och liknande resultatposter	*6*	242	75
Räntekostnader och liknande kostnader	*7*	-142	-95
Resultat efter finansiella poster		22 881	20 178
Resultat före skatt		22 881	20 178
Skatt på årets resultat	*8*	-5 148	-4 020
Årets resultat		**17 732**	**16 158**

DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

20230704322774

Balansräkning

Belopp i kkr	*Not*	*2022-12-31*	*2021-12-31*
TILLGÅNGAR			
Anläggningstillgångar			
Materiella anläggningstillgångar			
Maskiner och andra tekniska anläggningar	*9*	677	847
Förbättringsutg annans fastighet	*10*	93	96
		770	943
Summa anläggningstillgångar		770	943
Omsättningstillgångar			
Kortfristiga fordringar			
Kundfordringar		59 371	57 521
Fordringar hos koncernföretag		95 820	72 799
Skattefordringar		3 308	4 101
Övriga fordringar		-	245
Förutbetalda kostnader och upplupna intäkter	*11*	9 363	6 805
		167 862	141 471
Summa omsättningstillgångar		167 862	141 471
SUMMA TILLGÅNGAR		168 632	142 414

Balansräkning

Belopp i kkr	*Not*	*2022-12-31*	*2021-12-31*
EGET KAPITAL OCH SKULDER			
Eget kapital			
Bundet eget kapital			
Aktiekapital	*12*	35 000	35 000
Reservfond		7 000	7 000
		42 000	42 000
Fritt eget kapital	*13*		
Balanserad vinst eller förlust		21 012	4 854
Årets resultat		17 732	16 158
		38 744	21 012
Summa eget kapital		80 744	63 012
Kortfristiga skulder			
Leverantörsskulder		10 465	14 050
Skulder till koncernföretag		35 339	29 376
Övriga kortfristiga skulder		12 469	8 931
Upplupna kostnader och förutbetalda intäkter	*14*	29 615	27 045
		87 888	79 402
SUMMA EGET KAPITAL OCH SKULDER		168 632	142 414

Eli Lilly Sweden AB
556135-1171

Kassaflödesanalys

20230704322275

Belopp i kkr	*Not*	*2022-01-01-2022-12-31*	*2021-01-01-2021-12-31*
Den löpande verksamheten			
Rörelseresultat		22 781	20 197
Avskrivningar		172	164
Erhållen ränta		242	75
Erlagd ränta		-142	-95
Betald inkomstskatt		-4 357	-4 419
Kassaflöde från den löpande verksamheten före förändringar av rörelsekapital		**18 696**	**15 922**
Förändring i rörelsekapital			
Ökning(-)/Minskning (+) av rörelsefordringar		8 485	51 596
Ökning(+)/Minskning (-) av rörelseskulder		-27 181	-22 518
Kassaflöde från den löpande verksamheten		**-**	**45 000**
Investeringsverksamheten			
Förvärv av materiella anläggningstillgångar		-	-
Kassaflöde från investeringsverksamheten		**-**	**-**
Finansieringsverksamheten			
Utbetald utdelning till moderföretaget		-	-45 000
Kassaflöde från finansieringsverksamheten		**-**	**-45 000**
Årets kassaflöde		**-**	**-**
Likvida medel vid årets slut		**-**	**-**

DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

Rapport över förändringar i Eget kapital 2022

	Aktiekapital, nyemission under reg	*Reservfond övr bundna fonder*	*Balanserad vinst*	*Årets vinst*
Utgående balans 2021-12-31	**35 000**	**7 000**	**4 854**	**16 158**
Omföring av föreg års vinst			16 158	-16 158
Årets resultat				17 732
Utgående balans 2022-12-31	**35 000**	**7 000**	**21 012**	**17 732**

DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

Noter

Not 1 Redovisningsprinciper

Belopp i kkr om inget annat anges

Allmänna redovisningsprinciper

Årsredovisningen har upprättats i enlighet med årsredovisningslagen och Bokföringsnämndens allmänna råd BFNAR 2012:1 Årsredovisning och koncernredovisning (K3).

Värderingsprinciper m m

Tillgångar, avsättningar och skulder har värderats utifrån anskaffningsvärden om inget annat anges nedan.

Fordringar har värderats till det belopp varmed de beräknas inflyta.

Rörelsens intäkter redovisas vid leverans av produkter när risk och/eller äganderätt övergår till köparen.

Företaget redovisar samtliga leasingavtal, som operationella. Operationella leasingavtal redovisas som en kostnad linjärt över leasingperioden.

Materiella anläggningstillgångar

Materiella anläggningstillgångar redovisas till anskaffningsvärde minskat med ackumulerade avskrivningar och nedskrivningar. I anskaffningsvärdet ingår förutom inköpspriset även utgifter som är direkt hänförliga till förvärvet.

Avskrivningar

Materiella anläggningstillgångar	*År*
Inventarier, verktyg och installationer	20%

Avskrivningarna baseras på tillgångarnas beräknade ekonomiska livslängd och uppgår till 20 % av tillgångarnas anskaffningsvärden, vilket ej överskrider skattemässigt maximalt tillåtna avskrivningar.

Utländsk valuta

Tillgångar och skulder i utländsk valuta har värderats till balansdagens kurs.

Ersättningar till anställda

Beskrivningen nedan exemplifierar förhållanden som kan förekomma. Beskrivningen av redovisningsprinciperna måste anpassas och förändras utifrån tillämpade planer och förhållanden.

Ersättningar till anställda efter avslutad anställning

Klassificering
Planer för ersättningar efter avslutad anställning klassificeras som antingen avgiftsbestämda eller förmånsbestämda.
Vid avgiftsbestämda planer betalas fastställda avgifter till ett annat företag, normalt ett försäkringsföretag, och har inte längre någon förpliktelse till den anställde när avgiften är betald. Storleken på den anställdes ersättningar efter avslutad anställning är beroende av de avgifter som har betalat och den kapitalavkastning som avgifterna ger.

Vid förmånsbestämda planer har företaget en förpliktelse att lämna de överenskomna ersättningarna till nuvarande och tidigare anställda. Företaget bär i allt väsentligt dels risken att ersättningarna

20230704322776

kommer att bli högre än förväntat (aktuariell risk), dels risken att avkastningen på tillgångarna avviker från förväntningarna (investeringsrisk). Investeringsrisk föreligger även om tillgångarna är överförda till ett annat företag.

Avgiftsbestämda planer
Avgifterna för avgiftsbestämda planer redovisas som kostnad. Obetalda avgifter redovisas som skuld.
Förmånsbestämda planer
Företag har valt att tillämpa de förenklingsregler som finns i BFNAR 2012:1.

Övriga långfristiga ersättningar till anställda

Skuld avseende övriga långfristiga ersättningar till anställda redovisas till nuvärdet av förpliktelsen på balansdagen.

Ersättningar vid uppsägning

Ersättningar vid uppsägningar, i den omfattning ersättningen inte ger företaget några framtida ekonomiska fördelar, redovisas endast som en skuld och en kostnad när företaget har en legal eller informell förpliktelse att antingen
a) avsluta en anställds eller en grupp av anställdas anställning före den normala tidpunkten för anställningens upphörande, eller
b) lämna ersättningar vid uppsägning genom erbjudande för att uppmuntra frivillig avgång.
Ersättningar vid uppsägningar redovisas endast när företaget har en detaljerad plan för uppsägningen och inte har någon realistisk möjlighet att annullera planen.

Skatt

Skatt på årets resultat i resultaträkningen består av aktuell skatt och uppskjuten skatt. Aktuell skatt är inkomstskatt för innevarande räkenskapsår som avser årets skattepliktiga resultat och den del av tidigare räkenskapsårs inkomstskatt som ännu inte har redovisats. Uppskjuten skatt är inkomstskatt för skattepliktigt resultat avseende framtida räkenskapsår till följd av tidigare transaktioner eller händelser.

Uppskjuten skatteskuld redovisas för alla skattepliktiga temporära skillnader, dock inte för temporära skillnader som härrör från första redovisningen av goodwill. Uppskjuten skattefordran redovisas för avdragsgilla temporära skillnader och för möjligheten att i framtiden använda skattemässiga underskottsavdrag. Värderingen baseras på hur det redovisade värdet för motsvarande tillgång eller skuld förväntas återvinnas respektive regleras. Beloppen baseras på de skattesatser och skatteregler som är beslutade före balansdagen och har inte nuvärdesberäknats.

Uppskjutna skattefordringar har värderats till högst det belopp som sannolikt kommer att återvinnas baserat på innevarande och framtida skattepliktiga resultat. Värderingen omprövas varje balansdag.

Not Nyckeltalsdefinitioner

Balansomslutning:
Totala tillgångar.

Avkastning på eget kapital:
Årets resultat i % av justerat eget kapital.

Soliditet:
Justerat eget kapital i % av balansomslutning

DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

20230704322777

Not 2 Nettoomsättning

Nettoomsättning
Bolagets affärsverksamhet har påverkats av Corona-krisen på så sätt att bolagets anställda har arbetat hemifrån i den utsträckning detta har varit möjligt, samt att bolagets interaktioner med sjukvården har minskat kraftigt i respekt för sjukvårdens ökade belastning. Affärsverksamheten har bortsett från dessa två faktorer påverkats av Corona-krisen i begränsad omfattning.

Not 3 Anställda och personalkostnader

Medelantalet anställda

	2022-01-01-2022-12-31	*Varav män*	*2021-01-01-2021-12-31*	*Varav män*
Sverige	47	18	46	16
Totalt	**47**	**18**	**46**	**16**

Löner och andra ersättningar fördelade mellan styrelseledamöter m. fl. och övriga anställda

	2022-01-01-2022-12-31	*2021-01-01-2021-12-31**
Löner och andra ersättningar, styrelse och VD	8 801	7 341
Löner och andra ersättningar, Anställda	43 304	35 695
	52 105	**43 036**
Pensionskostnader för styrelse och VD	644	741
Pensionskostnader för övriga anställda	7 709	7 487
Sociala avgifter enligt lag och avtal	18 729	18 231
	27 082	**26 459**

Redovisning av könsfördelning i företagsledningar

	2022-12-31	*2021-12-31*
Andel kvinnor		
Styrelsen	33%	67%
Övriga ledande befattningshavare	67%	33%

Not 4 Arvode och kostnadsersättning till revisorer

	2022-01-01-2022-12-31	*2021-01-01-2021-12-31*
Ernst & Young		
Revisionsuppdrag	149	208

Not 5 Operationell leasing - leasetagare

	2022-01-01-2022-12-31	*2021-01-01-2021-12-31*
Bolaget har ingått hyresavtal av operationell natur enligt följande:		
Framtida minimileaseavgifter avseende icke uppsägningsbara operationella leasingavtal:		
Inom ett år	3 208	2 962
Mellan ett och fem år	5 530	3 570
Senare än fem år	-	-
	8 738	6 532

DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

Räkenskapsårets kostnadsförda leasingavgifter	3 266	3 254

Not 6 Ränteintäkter och liknande resultatposter

	2022-01-01-2022-12-31	*2021-01-01-2021-12-31*
Ränteintäkter, övriga	242	75
Summa	**242**	**75**

Not 7 Räntekostnader och liknande resultatposter

	2022-01-01-2022-12-31	*2021-01-01-2021-12-31*
Räntekostnader, övriga	-142	-95
Summa	**-142**	**-95**

Not 8 Skatt på årets resultat

	2022-01-01-2022-12-31	*2021-01-01-2021-12-31*
Aktuell skattekostnad	5 148	4 363
Skatt på grund av ändrad beskattning 2020	-	-343
	5 148	**4 020**

Avstämning av effektiv skatt

		2022-01-01-2022-12-31		*2021-01-01-2021-12-31*
Resultat före skatt		22 881		20 178
Skatt enligt gällande skattesats	20,6%	4 713	20,6%	4 157
Ej avdragsgilla kostnader		435		206
Skatt hänförlig till tidigare år		-		-343
Redovisad effektiv skatt		-5 148	21,6%	-4 020
Differens		**-**		**-**

Not 9 Inventarier, verktyg och installationer

	2022-12-31	*2021-12-31*
Ackumulerade anskaffningsvärden		
-Vid årets början	2 574	2 574
-Nyanskaffningar	-	-
	2 574	2 574
Ackumulerade avskrivningar		
-Vid årets början	-1 727	-1 566
-Årets avskrivning	-170	-161
	-1 897	-1 727
Redovisat värde vid årets slut	**677**	**847**

20230704322778

Not 10 Förbättringsutgifter på annans fastighet

	2022-12-31	*2021-12-31*
Ingående anskaffningsvärden	1 677	1 677
Förändringar av anskaffningsvärden	-	-
Utgående anskaffningsvärden	1 677	1 677
Ingående avskrivningar	-1 581	-1 579
Förändringar av avskrivningar		
Årets avskrivningar	-3	-2
Utgående avskrivningar	-1 584	-1 581
Redovisat värde	**93**	**96**

Not 11 Förutbetalda kostnader och upplupna intäkter

	2022-12-31	*2021-12-31*
Förutbetald läkemedelsförsäkring	1 109	-
Förutbetalda hyror	574	458
Förutbetalda pensioner	664	330
Övrigt	7 015	6 017
	9 362	**6 805**

Not 12 Antal aktier och kvotvärde

	2022-12-31	*2021-12-31*
A-aktier		
antal aktier	350 000	350 000
kvotvärde	100	100

Not 13 Disposition av vinst eller förlust

Förslag till disposition av företagets vinst eller förlust
Styrelsen föreslår att fritt eget kapital, kronor 38 744 103 disponeras enligt följande:

	2022-12-31
utdelning, [350 000 st * 85,71 kr]	30 000
Balanseras i ny räkning	8 744
	38 744

Not 14 Upplupna kostnader och förutbetalda intäkter

	2022-12-31	*2021-12-31*
Semesterlöneskuld	2 117	2 128
Sociala avgifter	2 167	1 735
Bonus till anställda	7 620	5 500
Upplupna säljkostnader	14 551	13 093
Övrigt	3 160	4 589
	29 615	**27 045**

DocuSign Envelope ID: B984A87F-783B-4CC3-A5C8-48099B9AA9D1

Not 15 Ställda säkerheter och eventualförpliktelser

Ställda säkerheter

	2022-12-31	*2021-12-31*
För egna skulder och avsättningar	*Inga*	*Inga*

Eventualförpliktelser

Eventualförpliktelser: Inga
I enlighet med Läkemedelsförsäkringsföreningens stadgar:
"Medlemmarna skall subsidiärt solidariskt svara gentemot föreningen för betalning av försäkringspremie, ersättning till försäkringsgivare för skaderegleringstjänster samt ersättning för läkemedelsskada som omfattas av självrisken."

Not 16 Väsentliga händelser efter räkenskapsårets slut

Bolagets affärsverksamhet har inte påverkats av några väsentliga justerande eller icke-justerande händelser efter räkenskapsårets utgång.

Not 17 Koncernuppgifter

Bolaget var vid utgången av räkenskapsåret helägt av Lilly Holdings, BV, Holland, vars årsredovisning finns tillgänglig på företagets kontor på Papendorpseweg 83, 3528 BJ, Utrecht, Holland. Yttersta moderbolag är Eli Lilly & Company, P.O. Box 88665, Indianapolis,Indiana 46208-0665, USA.

Inköp och försäljning inom koncernen
Av koncernens totala inköp och försäljning mätt i kronor avser 100 % av inköpen och 0 % av försäljningen andra företag inom hela den företagsgrupp som koncernen tillhör.

Inköp består till 100 % av koncernens produkter från tillverkande enheter utanför Sverige, t ex England, Frankrike, Italien m fl.

Bolaget ingår i koncernens cashpool vilket redovisas som en fordran på koncernföretag.

Eli Lilly Sweden AB
556135-1171

Underskrifter

Solna 28-06-2023

DocuSigned by:
Damir Mörk
D4E40845441F47F...
Damir Zadravec Mörk
Verkställande direktör och styrelseledamot

DocuSigned by:
Daniel Lucas
DFF9B9DD4E7E408...
Jose Daniel Lucas
Styrelseledamot och ordförande

DocuSigned by:
Helene Rathkjen
7A6F3C504D99473...
Helene Rathkjen Wallin
Styrelseledamot

Vår revisionsberättelse har lämnats 28-06-2023
Ernst & Young Aktiebolag

DocuSigned by:
9583EFA003F34FB...
Peter Gunnarsson
Auktoriserad revisor

20230704322279

20230704322280

Building a better working world

Revisionsberättelse

Till bolagsstämman i Eli Lilly Sweden AB, org.nr 556135-1171

Rapport om årsredovisningen

Uttalanden

Vi har utfört en revision av årsredovisningen för Eli Lilly Sweden AB för år 2022 med undantag för hållbarhetsrapporten på sidorna 2-4.

Enligt vår uppfattning har årsredovisningen upprättats i enlighet med årsredovisningslagen och ger en i alla väsentliga avseenden rättvisande bild av Eli Lilly Sweden ABs finansiella ställning per den 31 december 2022 och av dess finansiella resultat och kassaflöde för året enligt årsredovisningslagen. Våra uttalanden omfattar inte hållbarhetsrapporten på sidorna 2-4.

Förvaltningsberättelsen är förenlig med årsredovisningens övriga delar.

Vi tillstyrker därför att bolagsstämman fastställer resultaträkningen och balansräkningen.

Grund för uttalanden

Vi har utfört revisionen enligt International Standards on Auditing (ISA) och god revisionssed i Sverige. Vårt ansvar enligt dessa standarder beskrivs närmare i avsnittet *Revisorns ansvar*. Vi är oberoende i förhållande till Eli Lilly Sweden AB enligt god revisorssed i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för våra uttalanden.

Annan information än årsredovisningen

Detta dokument innehåller även annan information än årsredovisningen och återfinns på sidorna 2-4. Det är styrelsen och verkställande direktören som har ansvaret för denna andra information.

Vårt uttalande avseende årsredovisningen omfattar inte denna information och vi gör inget uttalande med bestyrkande avseende denna andra information.

I samband med vår revision av årsredovisningen är det vårt ansvar att läsa den information som identifieras ovan och överväga om informationen i väsentlig utsträckning är oförenlig med årsredovisningen. Vid denna genomgång beaktar vi även den kunskap vi i övrigt inhämtat under revisionen samt bedömer om informationen i övrigt verkar innehålla väsentliga felaktigheter.

Om vi, baserat på det arbete som har utförts avseende denna information, drar slutsatsen att den andra informationen innehåller en väsentlig felaktighet, är vi skyldiga att rapportera detta. Vi har inget att rapportera i det avseendet.

Styrelsens och verkställande direktörens ansvar

Det är styrelsen och verkställande direktören som har ansvaret för att årsredovisningen upprättas och att den ger en rättvisande bild enligt årsredovisningslagen. Styrelsen och verkställande direktören ansvarar även för den interna kontroll som de bedömer är nödvändig för att upprätta en årsredovisning som inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller på fel.

Vid upprättandet av årsredovisningen ansvarar styrelsen och verkställande direktören för bedömningen av bolagets förmåga att fortsätta verksamheten. De upplyser, när så är tillämpligt, om förhållanden som kan påverka förmågan att fortsätta verksamheten och att använda antagandet om fortsatt drift. Antagandet om fortsatt drift tillämpas dock inte om styrelsen och verkställande direktören avser att likvidera bolaget, upphöra med verksamheten eller inte har något realistiskt alternativ till att göra något av detta.

Revisorns ansvar

Våra mål är att uppnå en rimlig grad av säkerhet om att årsredovisningen som helhet inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller på fel, och att lämna en revisionsberättelse som innehåller våra uttalanden. Rimlig säkerhet är en hög grad av säkerhet, men är ingen garanti för att en revision som utförs enligt ISA och god revisionssed i Sverige alltid kommer att upptäcka en väsentlig felaktighet om en sådan finns. Felaktigheter kan uppstå på grund av oegentligheter eller fel och anses vara väsentliga om de enskilt eller tillsammans rimligen kan förväntas påverka de ekonomiska beslut som användare fattar med grund i årsredovisningen.

Som del av en revision enligt ISA använder vi professionellt omdöme och har en professionellt skeptisk inställning under hela revisionen. Dessutom:

- identifierar och bedömer vi riskerna för väsentliga felaktigheter i årsredovisningen, vare sig dessa beror på oegentligheter eller på fel, utformar och utför granskningsåtgärder bland annat utifrån dessa risker och inhämtar revisionsbevis som är tillräckliga och ändamålsenliga för att utgöra en grund för våra uttalanden. Risken för att inte upptäcka en väsentlig felaktighet till följd av oegentligheter är högre än för en väsentlig felaktighet som beror på fel, eftersom oegentligheter kan innefatta agerande i maskopi, förfalskning, avsiktliga utelämnanden, felaktig information eller åsidosättande av intern kontroll.
- skaffar vi oss en förståelse av den del av bolagets interna kontroll som har betydelse för vår revision för att utforma granskningsåtgärder som är lämpliga med hänsyn till omständigheterna, men inte för att uttala oss om effektiviteten i den interna kontrollen.
- utvärderar vi lämpligheten i de redovisningsprinciper som används och rimligheten i styrelsens och verkställande direktörens uppskattningar i redovisningen och tillhörande upplysningar.
- drar vi en slutsats om lämpligheten i att styrelsen och verkställande direktören använder antagandet om fortsatt drift vid upprättandet av årsredovisningen. Vi drar också en slutsats, med grund i de inhämtade revisionsbevisen, om det finns någon väsentlig osäkerhetsfaktor som avser sådana händelser eller förhållanden som kan leda till betydande tvivel om bolagets förmåga att fortsätta verksamheten. Om vi drar slutsatsen att det finns en väsentlig osäkerhetsfaktor, måste vi i revisionsberättelsen fästa uppmärksamheten på upplysningarna i årsredovisningen om den väsentliga

Penneo dokumentnyckel: V8LCW-1U4V7-1HQ58-1NSFE-5SVQG-TE7OI

osäkerhetsfaktorn eller, om sådana upplysningar är otillräckliga, modifiera uttalandet om årsredovisningen. Våra slutsatser baseras på de revisionsbevis som inhämtas fram till datumet för revisionsberättelsen. Dock kan framtida händelser eller förhållanden göra att ett bolag inte längre kan fortsätta verksamheten.

- utvärderar vi den övergripande presentationen, strukturen och innehållet i årsredovisningen, däribland upplysningarna, och om årsredovisningen återger de underliggande transaktionerna och händelserna på ett sätt som ger en rättvisande bild.

Vi måste informera styrelsen om bland annat revisionens planerade omfattning och inriktning samt tidpunkten för den. Vi måste också informera om betydelsefulla iakttagelser under revisionen, däribland de eventuella betydande brister i den interna kontrollen som vi identifierat.

Rapport om andra krav enligt lagar och andra författningar

Uttalanden

Utöver vår revision av årsredovisningen har vi även utfört en revision av styrelsens och verkställande direktörens förvaltning av Eli Lilly Sweden AB för år 2022 samt av förslaget till dispositioner beträffande bolagets vinst eller förlust.

Vi tillstyrker att bolagsstämman disponerar vinsten enligt förslaget i förvaltningsberättelsen och beviljar styrelsens ledamöter och verkställande direktören ansvarsfrihet för räkenskapsåret.

Grund för uttalanden

Vi har utfört revisionen enligt god revisionssed i Sverige. Vårt ansvar enligt denna beskrivs närmare i avsnittet *Revisorns ansvar*. Vi är oberoende i förhållande till Eli Lilly Sweden AB enligt god revisorssed i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för våra uttalanden.

Styrelsens och verkställande direktörens ansvar

Det är styrelsen som har ansvaret för förslaget till dispositioner beträffande bolagets vinst eller förlust. Vid förslag till utdelning innefattar detta bland annat en bedömning av om utdelningen är försvarlig med hänsyn till de krav som bolagets verksamhetsart, omfattning och risker ställer på storleken av bolagets egna kapital, konsolideringsbehov, likviditet och ställning i övrigt.

Styrelsen ansvarar för bolagets organisation och förvaltningen av bolagets angelägenheter. Detta innefattar bland annat att fortlöpande bedöma bolagets ekonomiska situation och att tillse att bolagets organisation är utformad så att bokföringen, medelsförvaltningen och bolagets ekonomiska angelägenheter i övrigt kontrolleras på ett betryggande sätt. Den verkställande direktören ska sköta den löpande förvaltningen enligt styrelsens riktlinjer och anvisningar och bland annat vidta de åtgärder som är nödvändiga för att bolagets bokföring ska fullgöras i överensstämmelse med lag och för att medelsförvaltningen ska skötas på ett betryggande sätt.

Revisorns ansvar

Vårt mål beträffande revisionen av förvaltningen, och därmed vårt uttalande om ansvarsfrihet, är att inhämta revisionsbevis för att med en rimlig grad av säkerhet kunna bedöma om någon styrelseledamot eller verkställande direktören i något väsentligt avseende:

- företagit någon åtgärd eller gjort sig skyldig till någon försummelse som kan föranleda ersättningsskyldighet mot bolaget, eller
- på något annat sätt handlat i strid med aktiebolagslagen, årsredovisningslagen eller bolagsordningen.

Vårt mål beträffande revisionen av förslaget till dispositioner av bolagets vinst eller förlust, och därmed vårt uttalande om detta, är att med rimlig grad av säkerhet bedöma om förslaget är förenligt med aktiebolagslagen.

Rimlig säkerhet är en hög grad av säkerhet, men ingen garanti för att en revision som utförs enligt god revisionssed i Sverige alltid kommer att upptäcka åtgärder eller försummelser som kan föranleda ersättningsskyldighet mot bolaget, eller att ett förslag till dispositioner av bolagets vinst eller förlust inte är förenligt med aktiebolagslagen.

Som en del av en revision enligt god revisionssed i Sverige använder vi professionellt omdöme och har en professionellt skeptisk inställning under hela revisionen. Granskningen av förvaltningen och förslaget till dispositioner av bolagets vinst eller förlust grundar sig främst på revisionen av räkenskaperna. Vilka tillkommande granskningsåtgärder som utförs baseras på vår professionella bedömning med utgångspunkt i risk och väsentlighet. Det innebär att vi fokuserar granskningen på sådana åtgärder, områden och förhållanden som är väsentliga för verksamheten och där avsteg och överträdelser skulle ha särskild betydelse för bolagets situation. Vi går igenom och prövar fattade beslut, beslutsunderlag, vidtagna åtgärder och andra förhållanden som är relevanta för vårt uttalande om ansvarsfrihet. Som underlag för vårt uttalande om styrelsens förslag till dispositioner beträffande bolagets vinst eller förlust har vi granskat styrelsens motiverade yttrande samt ett urval av underlagen för detta för att kunna bedöma om förslaget är förenligt med aktiebolagslagen.

Revisorns yttrande avseende den lagstadgade hållbarhetsrapporten

Det är styrelsen som har ansvaret för hållbarhetsrapporten på sidorna 2-4 och för att den är upprättad i enlighet med årsredovisningslagen.

Vår granskning har skett enligt FARs rekommendation RevR 12 *Revisorns yttrande om den lagstadgade hållbarhetsrapporten*. Detta innebär att vår granskning av hållbarhetsrapporten har en annan inriktning och en väsentligt mindre omfattning jämfört med den inriktning och omfattning som en revision enligt International Standards on Auditing och god revisionssed i Sverige har. Vi anser att denna granskning ger oss tillräcklig grund för vårt uttalande.

En hållbarhetsrapport har upprättats.

Malmö den dag som framgår av vår elektroniska underskrift

Ernst & Young AB

Peter Gunnarsson

Auktoriserad revisor

Penneo dokumentnyckel: V8L-CW-1U4V7-1HQ58-1NSFE-S5VQG-TE7OL

Signaturerna i detta dokument är juridiskt bindande. Dokumentet är signerat genom Penneo™ för säker digital signering. Tecknarnas identitet har lagrats, och visas nedan.

"Med min signatur bekräftar jag innehållet och alla datum i detta dokumentet."

Lars Johan Peter Gunnarsson
Auktoriserad revisor
Serienummer: 19720328xxxx
IP: 145.62.xxx.xxx
2023-06-28 12:48:04 UTC

BankID

Penneo dokumentnyckel: V8LCW-U4V7-1HQ58-1NSFE-S5VQG-TE7OL

20230704322831

Detta dokument är digitalt signerat genom Penneo.com. Den digitala signeringsdatan i dokumentet är säkrad och validerad genom det datorgenererade hashvärdet hos det originella dokumentet. Dokumentet är låst och tidsstämplat med ett certifikat från en betrodd tredje part. All kryptografisk information är innesluten i denna PDF, för framtida validering om så krävs.

Hur man verifierar originaliteten hos dokumentet
Detta dokument är skyddat genom ett Adobe CDS certifikat. När du öppnar dokumentet i Adobe Reader bör du se att dokumentet är certifierat med **Penneo e-signature service <penneo@penneo.com>** Detta garanterar att dokumentets innehåll inte har ändrats.

Du kan verifiera den kryptografiska informationen i dokumentet genom att använda Penneos validator, som finns på **https://penneo.com/validator**

DocuSign

Certificate Of Completion

Envelope Id: B984A87F783B4CC3A5C848099B9AA9D1
Status: Completed
Subject: Complete with DocuSign: 2 - Eli Lilly Sweden AB ÅR 2022 SWE 28.06.2023.pdf
Source Envelope:
Document Pages: 17
Signatures: 5
Certificate Pages: 51
Initials: 0
AutoNav: Enabled
EnvelopeId Stamping: Enabled
Time Zone: (UTC) Dublin, Edinburgh, Lisbon, London

Envelope Originator:
Helene Rathkjen
Lilly Corporate Center
Indianapolis, IN 46285-0001
rathkjen_helene@lilly.com
IP Address: 148.64.14.195

Record Tracking

Status: Original
6/28/2023 10:30:17 AM
Holder: Helene Rathkjen
rathkjen_helene@lilly.com
Location: DocuSign

Signer Events	Signature	Timestamp
Damir Mörk mork_damir@lilly.com Country Lead Eli Lilly Sweden Security Level: Email, Account Authentication (None), Digital Certificate **Signature Provider Details:** Signature Type: DocuSign Protect & Sign (Client ID: DDE5E85D-4085-40B6-8785-DA3CCD16D81E) Signature Issuer: DocuSign Cloud Signing CA - SI1 Authentication: Access Code **Electronic Record and Signature Disclosure:** Accepted: 6/12/2023 7:09:05 AM ID: d0999dfe-6b8a-47c7-be01-1e4ec6dcd146	DocuSigned by: Damir Mörk D4E40845441F47F... Signature Adoption: Pre-selected Style Using IP Address: 199.247.35.193 Signature Provider Location: https://ps-ws.dsf.docusign.net/ds-server/s/noauth/psm/tsp/sign	Sent: 6/28/2023 11:41:24 AM Viewed: 6/28/2023 11:42:04 AM Signed: 6/28/2023 11:43:36 AM
Daniel Lucas lucas_daniel@lilly.com Security Level: Email, Account Authentication (None), Digital Certificate **Signature Provider Details:** Signature Type: DocuSign Protect & Sign (Client ID: DDE5E85D-4085-40B6-8785-DA3CCD16D81E) Signature Issuer: DocuSign Cloud Signing CA - SI1 Authentication: Access Code **Electronic Record and Signature Disclosure:** Accepted: 6/28/2023 11:56:29 AM ID: 0330f61b-7011-4947-a9ff-f7e748b37088	DocuSigned by: Daniel Lucas DFF9B9DD4E7E408... Signature Adoption: Pre-selected Style Using IP Address: 40.228.31.12 Signature Provider Location: https://ps-ws.dsf.docusign.net/ds-server/s/noauth/psm/tsp/sign	Sent: 6/28/2023 11:43:40 AM Viewed: 6/28/2023 11:56:29 AM Signed: 6/28/2023 11:57:38 AM
Helene Rathkjen rathkjen_helene@lilly.com Security Level: Email, Account Authentication (None), Digital Certificate **Signature Provider Details:** Signature Type: DocuSign Protect & Sign (Client ID: DDE5E85D-4085-40B6-8785-DA3CCD16D81E) Signature Issuer: DocuSign Cloud Signing CA - SI1 Authentication: Access Code **Electronic Record and Signature Disclosure:** Not Offered via DocuSign	DocuSigned by: Helene Rathkjen 7A6F3C504D99473... Signature Adoption: Pre-selected Style Using IP Address: 148.64.14.195 Signature Provider Location: https://ps-ws.dsf.docusign.net/ds-server/s/noauth/psm/tsp/sign	Sent: 6/28/2023 11:57:42 AM Viewed: 6/28/2023 12:02:18 PM Signed: 6/28/2023 12:03:10 PM

20230704322282

Signer Events	Signature	Timestamp
Peter Gunnarsson Peter.gunnarsson@se.ey.com Security Level: Email, Account Authentication (None), Digital Certificate **Signature Provider Details:** Signature Type: DocuSign Protect & Sign (Client ID: DDE5E85D-4085-40B6-8785-DA3CCD16D81E) Signature Issuer: DocuSign Cloud Signing CA - SI1 Authentication: Access Code **Electronic Record and Signature Disclosure:** Accepted: 6/28/2023 12:07:26 PM ID: 5d076b3d-506f-4630-b665-21228fa3ee8e	DocuSigned by: 9583EFA003F34FB...	Sent: 6/28/2023 12:03:14 PM Viewed: 6/28/2023 12:07:26 PM Signed: 6/28/2023 1:46:08 PM
	Signature Adoption: Uploaded Signature Image Using IP Address: 84.216.56.2	
	Signature Provider Location: https://ps-ws.dsf.docusign.net/ds-server/s/noauth/psm/tsp/sign	

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp

Agent Delivery Events	Status	Timestamp

Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp

Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	6/28/2023 11:41:24 AM
Certified Delivered	Security Checked	6/28/2023 12:07:26 PM
Signing Complete	Security Checked	6/28/2023 1:46:08 PM
Completed	Security Checked	6/28/2023 1:46:08 PM

Payment Events	Status	Timestamps

Electronic Record and Signature Disclosure

Electronic Record and Signature Disclosure created on: 12/27/2021 8:30:04 AM
Parties agreed to: Damir Mörk

202307043228 3

UK

Ireland

South Africa

Australia & New Zealand

Israel

United Kingdom

Terms of use

In order to provide You with certain services as part of the relationship between You and Eli Lilly and Company or any of its subsidiaries (hereinafter, we, us or Lilly), particularly the electronic signature for contracted services, Lilly has engaged DocuSign Inc to manage electronic signature, based on an email procedure.

To that effect, Lilly might share with DocuSign, acting as data processor for Lilly, certain data as your email address, in order to allow tracking of the documents being signed and reminders or to provide to you certain written notices electronically. Any data to be disclosed by Lilly and/or captured by DocuSign is to support and facilitate the signing of the contract.

To use this service it is not compulsory upon You to create a DocuSign User account. If You voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following Lilly_UK_CMS@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Please, be aware that if you elect not to use the electronic signature service and electronic communications, it will slow the speed at which we can complete certain steps in transactions with You.

Your privacy is important to us. This Privacy Statement explains how Eli Lilly and Company (Lilly) collects personal data about you, why we collect it, and with whom we may share it. It also explains your rights with regard to this personal data. This Privacy Statement applies to all

personal data about you, regardless of whether the information is stored electronically or in hard copy.

Information We Collect and How We Use It

Your personal information, including your name, electronic signature and IP address will be used by Lilly or third parties acting on our behalf, for the purpose of creating and processing your contracts with Lilly. We may also use the information to meet legal or regulatory obligations, inclusive of company record retention that are in the legitimate interest of Lilly.

Your information may be combined with information from other public sources or other interactions we have with you.

To use this service it is not compulsory upon you to create a DocuSign User account. If you voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_uk_cms@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Processing operations may include the recording, organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction of personal data.

Reasons We Share Your Information

We may share your personal information with other Lilly affiliates and its agents and vendors worldwide for purposes consistent with those identified in this notice. All third parties that have access to your information have agreed to protect the information and to use it only as directed by us.

We may also be required to disclose your information in response to lawful requests by public authorities, including to comply with national security or law enforcement requests.

20230704322841

Where We Store and Process Your Information

We may transmit personal information about you to other Lilly affiliates worldwide. These affiliates may in turn transmit personal information about you to other Lilly affiliates. Some of Lilly's affiliates may be located in countries that do not ensure an adequate level of data protection. Nevertheless, all of Lilly's affiliates are required to treat personal information in a manner consistent with this notice. To obtain additional information regarding the basis for transfers and safeguards that Lilly has in place for cross-border transfers of personal information, please contact us at privacy@lilly.com or visit https://www.lilly.com/privacy.

How Long We Keep Your Information

Your information will be saved for a period of time needed to fulfill legitimate and lawful business purposes in accordance with Lilly's records retention policies and applicable laws and regulations.

How We Secure Your Information

We provide reasonable physical, electronic, and procedural safeguards to protect information we process and maintain. We limit access to your information to authorized employees, agents, contractors, vendors, subsidiaries, and business partners, or others who need such access to information to carry out their assigned roles and responsibilities on behalf of Lilly. Please be aware, although we try to protect the information we process and maintain, no security system can prevent all potential security breaches.

Your Rights and Choices

You have the right to request information from us on how your personal information is being used and with whom that information is being shared. You also have the right to request to see and get a copy of the personal information that we have about you, request its correction or request its erasure.

You also have the right to have your information transmitted to another entity or person in a machine-readable format, in limited circumstances. There may be limitations on our ability to comply with your request.

You, as a signee and/or authorized user of the DocuSign system may have access to and print a copy of any record provided or made available electronically to you by Lilly through DocuSign, by any of these means

- You can access the documents via the link originally provided in the email;
- You may contact our Customer Meetings Services via telephone at the following number: 020 3684 0772 - Selecting option 2 or
- If you have voluntarily created a DocuSign user account, you can login and see all documents sent to the email address connected with that account. Such account would be between You and DocuSign and not connected to Lilly; therefore Lilly would not take any responsibility for this and all legal notices applying are those of DocuSign.

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at lilly_uk_cms@lilly.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address.

In addition, if you have created a DocuSign user account you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

How to Contact Us

You may make any of the above requests by contacting us at:
Eli Lilly and Company Limited
Lilly House,
Priestley Road,
Basingstoke,
Hampshire,
RG24 9NL
Tel: 020 3684 0772 - Selecting option 2

How to Submit a Complaint

If you wish to raise a complaint on how we have handled your personal information, you can contact our Data Protection Officer at privacy@lilly.com who will investigate the matter.

If you are not satisfied with our response or believe we are processing your personal information not in accordance with the law you can register a complaint with a Data Protection Authority (DPA).

20230704322285

Ireland

Terms of use

In order to provide You with certain services as part of the relationship between You and Eli Lilly and Company or any of its subsidiaries (hereinafter, we, us or Lilly), particularly the electronic signature for contracted services, Lilly has engaged DocuSign Inc to manage electronic signature, based on an email procedure.

To that effect, Lilly might share with DocuSign, acting as data processor for Lilly, certain data as your email address, in order to allow tracking of the documents being signed and reminders or to provide to you certain written notices electronically. Any data to be disclosed by Lilly and/or captured by DocuSign is to support and facilitate the signing of the contract.

To use this service it is not compulsory upon You to create a DocuSign User account. If You voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_ireland_cms@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Please, be aware that if you elect not to use the electronic signature service and electronic communications, it will slow the speed at which we can complete certain steps in transactions with You.

Your privacy is important to us. This Privacy Statement explains how Eli Lilly and Company (Lilly) collects personal data about you, why we collect it, and with whom we may share it. It also explains your rights with regard to this personal data. This Privacy Statement applies to all personal data about you, regardless of whether the information is stored electronically or in hard copy.

Information We Collect and How We Use It

Your personal information, including your name, electronic signature and IP address will be used by Lilly or third parties acting on our behalf, for the purpose of creating and processing your

contracts with Lilly. We may also use the information to meet legal or regulatory obligations, inclusive of company record retention that are in the legitimate interest of Lilly.

Your information may be combined with information from other public sources or other interactions we have with you.

To use this service it is not compulsory upon you to create a DocuSign User account. If you voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_ireland_cms@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Processing operations may include the recording, organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction of personal data.

Reasons We Share Your Information

We may share your personal information with other Lilly affiliates and its agents and vendors worldwide for purposes consistent with those identified in this notice. All third parties that have access to your information have agreed to protect the information and to use it only as directed by us.

We may also be required to disclose your information in response to lawful requests by public authorities, including to comply with national security or law enforcement requests.

Where We Store and Process Your Information

We may transmit personal information about you to other Lilly affiliates worldwide. These affiliates may in turn transmit personal information about you to other Lilly affiliates. Some of Lilly's affiliates may be located in countries that do not ensure an adequate level of data protection. Nevertheless, all of Lilly's affiliates are required to treat personal information in a manner consistent with this notice. To obtain additional information regarding the basis for transfers and safeguards that Lilly has in place for cross-border transfers of personal information, please contact us at privacy@lilly.com or visit https://www.lilly.com/privacy.

20230704322B6

How Long We Keep Your Information

Your information will be saved for a period of time needed to fulfill legitimate and lawful business purposes in accordance with Lilly's records retention policies and applicable laws and regulations.

How We Secure Your Information

We provide reasonable physical, electronic, and procedural safeguards to protect information we process and maintain. We limit access to your information to authorized employees, agents, contractors, vendors, subsidiaries, and business partners, or others who need such access to information to carry out their assigned roles and responsibilities on behalf of Lilly. Please be aware, although we try to protect the information we process and maintain, no security system can prevent all potential security breaches.

Your Rights and Choices

You have the right to request information from us on how your personal information is being used and with whom that information is being shared. You also have the right to request to see and get a copy of the personal information that we have about you, request its correction or request its erasure.

You also have the right to have your information transmitted to another entity or person in a machine-readable format, in limited circumstances. There may be limitations on our ability to comply with your request.

You, as a signee and/or authorized user of the DocuSign system may have access to and print a copy of any record provided or made available electronically to you by Lilly through DocuSign, by any of these means:

- You can access the documents via the link originally provided in the email;
- You may contact our Customer Meetings Services via telephone at the following number: 020 3684 0772 - Selecting option 2 or
- If you have voluntarily created a DocuSign user account, you can login and see all documents sent to the email address connected with that account. Such account would be between You and DocuSign and not connected to Lilly; therefore Lilly would not take any responsibility for this and all legal notices applying are those of DocuSign.

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at lilly_ireland_cms@lilly.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address.

In addition, if you have created a DocuSign user account you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

How to Contact Us

You may make any of the above requests by contacting us at:
Eli Lilly and Company Limited
Lilly House,
Priestley Road,
Basingstoke,
Hampshire,
RG24 9NL
Tel: 020 3684 0772 - Selecting option 2

How to Submit a Complaint

If you wish to raise a complaint on how we have handled your personal information, you can contact our Data Protection Officer at privacy@lilly.com who will investigate the matter.

If you are not satisfied with our response or believe we are processing your personal information not in accordance with the law you can register a complaint with a Data Protection Authority (DPA).

South Africa

Agreement to do business with Eli Lilly and Company

USER NOTICE

20230704322287

- Terms of use
- Access to Document history by You
- Changes of e-mail address
- Privacy statement
- Required hardware and software

Terms of use

In order to provide You with certain services as part of the relationship between You and Eli Lilly and Company or any of its subsidiaries (hereinafter, we, us or Lilly), particularly the electronic signature for contracted services, Lilly has engaged DocuSign Inc to manage electronic signature, based on an email procedure.

To that effect, Lilly might share with DocuSign, acting as data processor for Lilly, certain data as your email address, in order to allow tracking of the documents being signed and reminders or to provide to you certain written notices electronically. Any data to be disclosed by Lilly and/or captured by DocuSign is to support and facilitate the signing of the contract.

To use this service it is not compulsory upon you to create a DocuSign User account. If you voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following Lilly_southafrica_CMS@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Please, be aware that if you elect not to use the electronic signature service and electronic communications, it will slow the speed at which we can complete certain steps in transactions with you.

Access to Document history by you

You, as a signee and/or authorized user of the DocuSign system may have access to and print a copy of any record provided or made available electronically to you by Lilly through DocuSign, by any of these means:

- You can access the documents via the link originally provided in the email;
- You may contact our Customer Meetings Services via email lilly_southafrica_CMS@lilly.com; or
- If you have voluntarily created a DocuSign user account, you can login and see all documents sent to the email address connected with that account. Such account would be between you and DocuSign and not connected to Lilly; therefore, Lilly would not take any responsibility for this and all legal notices applying are those of DocuSign.

Changes of e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at Lilly_southafrica_CMS@lilly.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address.

In addition, if you have created a DocuSign user account you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

Privacy Statement

Your privacy is important to us. This Privacy Statement is intended to let you know what information Eli Lilly South Africa may collect about you and how we use that information. This Privacy Statement applies to websites that link to this statement when you click on "Privacy Statement" in the website footer, as well as mobile applications and digital services that link to or post this Privacy Statement. In this Privacy Statement, we will refer to the websites, Apps, and Digital Services that may link to or post this Privacy Statement as “websites.”

Information We Collect and How We Use It

- Summary. This website may collect Personal Information that either directly identifies you or could be used in combination with other information to identify you. Examples of Personal Information that directly identify you include your name, contact information, email address, and other information in combination with identifiers. Our websites may also collect Personal Information that does not directly identify you by name or contact information but which may be used to identify that a specific computer or device has accessed our website.

20230704322888

Through this website we may collect the following information about you:

- Contact information. This might include information such as your name, address, telephone number, e-mail address, and other similar information ("Personal Information"). We collect this information so that we can communicate with you. You may always refuse to provide Personal Information to us, but then we may not be able to provide you with certain information, products, or services.
- Additional Information. Certain areas of our Websites allow you to share additional Personal Information with us. For example, you may subscribe to one of our mailing lists or newsletters. We may use the information you provide to send your requested information, respond to your inquiry, improve our websites, verify your relationship with us, and take other actions that may be necessary to respond to your request.
- Interests and preferences. This information lets us better understand how to best serve you based on your interest in our products and services. This information may include your preferences about how to contact you, further develop a business or professional relationship, understand product preferences, languages, marketing preferences and some demographic data. Some of this information we collect with your consent and some of this information we collect automatically for our legitimate business purposes.
- Website Usage. We use this information to manage and secure our websites, network systems and other assets. This may include information about your IP ("Internet Protocol") address, the date and time of your website session, geographic location, and how you have navigated the website, and other information collected through our weblogs, cookies or in other ways. This may also include information that does not directly identify you but which corresponds to your device. It is possible that your IP Address, or a cookie that we use, may contain information that may be considered Personal Information. How we use Cookies and other technologies is described in more detail below. This information is collected automatically, for our legitimate business purposes.

We may also use the information to meet legal or regulatory obligations, such as adverse event reporting or to enforce our rights; and for company record retention, website management, research and product development that are in the legitimate interest of Lilly.

Where permitted by law, we may also enhance or merge information about you, including Personal Information, with information about you obtained from third parties for the same purposes shared above. Your information may also be used for profiling for the same purposes shared above. You may object to profiling via automated-decision making by contacting us using the information in the "How to Contact Us" section below.

Cookies and Similar Technologies

Web beacons

This site may use a technology known as web beacons that allows the collection of web log information. A web beacon is a tiny graphic on a web page or in an e-mail message designed to track pages viewed or messages opened. Web log information is gathered when you visit one of our websites by the computer that hosts our website (called a "webserver").

On certain web pages or in emails we send to you, we may utilize a technology called a “web beacon” (also known as an “action tag” or “clear GIF technology”). We may use web beacons to help determine which email messages sent by us were opened and whether a message was acted upon. Web beacons also help analyze the effectiveness of websites by measuring the number of visitors to a site or how many visitors clicked on key elements of a site.

Cookies

This website may use a technology called a "cookie". A cookie is a small data file that a website can place on your computer’s hard drive, where your internet browser files are kept. A cookie saves you the trouble of reentering certain information in some registration areas because cookies can be used to enable a site to “remember” information a visitor has previously inputted. A cookie also helps deliver content used -specific information to you and track how sections of the website are used. Cookies can be placed on your computer both by us and by third parties with whom we have a relationship, such as web analytic services and advertising network services. With most Internet browsers or other software, you can change your browser settings to erase cookies from your computer hard drive, block all cookies or receive a warning before a cookie is stored. Please check your browser instructions to learn more about these functions. If you reject cookies, functionality of the site may be limited, and you may not be able to take advantage of many of the site's features.

Do Not Track

There are different ways you can prevent tracking of your online activity. One of them is setting a preference in your browser that alerts websites you visit that you do not want them to collect certain information about you. This is referred to as a Do-Not-Track (“DNT”) signal. Please note that currently our websites and web-based resources do not respond to these signals from web browsers. At this time, there is no universally accepted standard for what a company should do when a DNT signal is detected.

Reasons Your Information is Shared

We may share your Personal Information with our agents, contractors or partners in connection with work that they do for, or with, Lilly, such as sending email messages, managing data, hosting our databases, providing data processing services, providing customer service, or so we may enhance or add data about you from these other entities. These agents, contractors or partners are restricted from using this data in any way other than to provide services for us, or services for the collaboration in which they are engaged with us (for example, some of our products are developed and marketed through joint agreements with other companies).

20230704322289

We will share Personal Information to respond to subpoenas or other lawful information requests of governmental authorities, including to meet national security or law enforcement requirements, to provide Internet security, or where required by law. In exceptionally rare circumstances where national, state or company security is at issue, we reserves the right to share our entire database of visitors and customers with appropriate governmental authorities.

We may also provide your Personal Information to a third party in connection with the sale, assignment, or other transfer of the business of a website to which the information relates, in which case we will require any such buyer to agree to treat Personal Information in accordance with this Privacy Statement.

Google Analytics

Google Analytics may be used to help make our website work better and to help us understand what parts of the website are being utilized. Google Analytics uses technical tools such as, First-party cookies and JavaScript code, to collect information about visitors. Google Analytics service tracks visitors to the site who have JavaScript enabled. Google Analytics anonymously tracks how visitors interact with a website, including where they came from and what they did on a site. Google Analytics collects the information set forth above from users.

This information is used to administer and update the website, and we will also assess whether the visitors to the site match the expected site demographics and determine how key audiences are navigating the content.

First-party cookies (such as the Google Analytics cookie) and third-party cookies (such as the DoubleClick cookie) will be used to report how your ad impressions, other uses of ad services, and interactions with these ad impressions and ad services are related to visits to this site.

A. Opt-Out Provision:
   Google analytics offers an opt-out provision for website visitors who do not want their data to be collected. You can receive more information about this option here:http://tools.google.com/dlpage/gaoptout
B. Google's Use of Data:
   Google and its wholly owned subsidiaries may retain and use, subject to the terms of its Privacy Policy (located at http://www.google.com/privacy.html, or such other URL as Google may provide from time to time), information collected in your use of the Google Analytics Information Disclosures and Sharing.
C.
D.

Social Media Plugins

Our websites may use Social Media Plugins to enable you to easily share information with others. When you visit our websites, the operator of the social media plugin that is

on our website can place a cookie on your computer that lets that operator to recognize individuals on their website who have previously visited our sites. If you have previously logged into the social media website while browsing on our website, social media plugins may allow that social media website to receive directly identifiable information about you that shows you have visited our website. The social media plugin may collect this information for visitors who have logged into social networks, whether or not they specifically interact with the plugin on our website. Social media plugins also allow the social media website to share information about your activities on our website with other users of their social media website. Lilly does not control any of the content from social media plugins. For more information about social plugins from social media websites you should refer to those sites' privacy and data sharing statements.

How Long We Keep Your Information

Your Information will be saved for a period of time needed to fulfill legitimate and lawful business purposes in accordance with our records retention policies and applicable laws and regulations.

Children's Information

This site is not intended for or designed for individuals under the age of 18. We do not knowingly collect Personal Information from any person under the age of 18.

How We Secure Your Information

We provide reasonable physical, electronic, and procedural safeguards to protect Personal Information collected via this website. For example, we limit access to this information to authorized employees, service providers, and contractors who need access to perform the activities described in this notice. Although we strive to provide reasonable security for information we process and maintain, no security system can prevent all potential security breaches.

Your Rights and Choices

You have the right to request information from us on how your personal information is being used and with whom that information is being shared. You also have the right to

20230704322290

see and get a copy of the personal information that we have about you. If you believe any of this information to be inaccurate or incomplete, you have the right to request its correction or erasure.

There may be limitation on our ability to comply with your request.

How to Contact Us

You may make any of the above requests by contacting us at:
ELI LILLY (S.A.) (PTY) LTD
First Floor, Golden Oak House, BallyOaks Office Park, 35 Ballyclare Drive, Bryanston, South Africa, 2191
+27 11 510 9370
privacy_za@lilly.com

You may also contact us at the above if you have questions about this Privacy Statement.

How to Submit a Complaint

If you wish to raise a complaint on how we have handled your personal information, you can contact us at:
ELI LILLY (S.A.) (PTY) LTD
First Floor, Golden Oak House, BallyOaks Office Park, 35 Ballyclare Drive, Bryanston, South Africa, 2191
+27 11 510 9370
privacy_za@lilly.com

If you are not satisfied with our response or believe we are processing your personal information not in accordance with the law you can register a complaint with a Data Protection Authority (DPA).

Links to Third Party Websites

As a convenience to our visitors, this Website may contain links to other sites owned and operated by third parties that we believe may offer useful information. The policies and procedures we describe here do not apply to those sites. We are not responsible for the collection or use of Personal Information at any third party sites. Therefore, we disclaim any liability for any third party's use of Personal Information obtained through using the

third party web site. We suggest contacting those sites directly for information on their privacy, security, data collection, and distribution policies.

Transfer of Personal Information Internationally

Lilly may transmit personal information about you to other Lilly affiliates worldwide. These affiliates may in turn transmit personal information about you to other Lilly affiliates. Some of Lilly's affiliates may be located in countries that do not ensure an adequate level of data protection. Nevertheless, all of Lilly's affiliates are required to treat personal information in a manner consistent with this notice.

Changes to Our Privacy Practices

We may update this Privacy Statement from time to time. When we do update it, for your convenience, we will make the updated statement available on this page. We will always handle your Personal Information in accordance with the Privacy Statement in effect at the time it was collected. We will not make any materially different use or new disclosure of your Personal Information to another entity using your Personal Information for its own purposes unless we notify you and give you an opportunity to object.

Last Updated: 14th February 2020

For more information about how Lilly companies in the U.S. process the personal information originating from South Africa, see the Lilly Privacy Notice available above

Your data will be kept for at least as long as the contract is retained. You have the right to review and correct, where needed, your personal information.

If you have questions about the information we process about you, please contact: Lilly_southafrica_CMS@lilly.com

Australia & New Zealand

Agreement to do business with Eli Lilly and Company

20230704322291

USER NOTICE

- Terms of use
- Access to Document history by You
- Changes of e-mail address
- Privacy statement
- Required hardware and software

Terms of use

In order to provide You with certain services as part of the relationship between You and Eli Lilly and Company or any of its subsidiaries (hereinafter, we, us or Lilly), particularly the electronic signature for contracted services, Lilly has engaged DocuSign Inc to manage electronic signatures, based on an email procedure.

To that effect, Lilly might share with DocuSign, acting as data processor for Lilly, certain data such as your email address, in order to allow tracking of the documents being signed and reminders or to provide to you certain written notices electronically. Any data to be disclosed by Lilly and/or captured by DocuSign is to support and facilitate the signing of documents.

To use this service, it is not compulsory that you create a DocuSign User account. If you voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no liability or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_anz_cms@lilly.com. Additionally, if you have created a DocuSign User account, to withdraw your consent you must use the DocuSign "Withdraw Consent" form on the signing page of your DocuSign User account. Lilly has no responsibility in that regard.

Please, be aware that if you elect not to use the electronic signature service and electronic communications, it will slow the speed at which we can complete certain steps in transactions with you.

Access to Document history by you

You, as a signee and/or authorized user of the DocuSign system may have access to and print a copy of any record provided or made available electronically to you by Lilly through DocuSign, by any of these means:

- You can access the documents via the link originally provided in the email;
- You may contact our Customer Meetings Services via email at lilly_anz_cms@lilly.com; or
- If you have voluntarily created a DocuSign User account, you can login and see all documents sent to the email address connected with your User account. Your account is between you and DocuSign and not connected to Lilly; therefore, Lilly takes no responsibility for your User account and all legal notices applying are those of DocuSign.

Changes of e-mail address

To let Lilly know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at lilly_anz_cms@lilly.com and in the body of such request please state: your previous e-mail address, your new e-mail address. Alternatively, you can update your contact information via the WebServices Portal.

If you have created a DocuSign User account you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign User account by following the process for changing e-mail in DocuSign.

Privacy Statement

As indicated at the beginning of this notice, for the purpose of facilitating electronically signing documents, we will capture some personal information like name, email address, IP address, a series of dates (sent/viewed/signed), whether you signed using the DocuSign mobile app or not and an image of the signature used.

Your personal information will be retained by Lilly and, in accordance with the purposes set out above, some personal information may be disclosed to other Lilly affiliates, (located outside Australia, including Eli Lilly and Company located at Indianapolis, Indiana, U.S.A.), to selected third party service providers and as required by law or industry codes of conduct. U.S. or other foreign government agencies may be able to obtain access to your personal information under

20230704322292

applicable law. For questions about the collection, use of disclosure of personal information, to request access, correction or deletion of personal information held by Lilly about the HCP, or to make a complaint about the handling of personal information, contact Lilly's Privacy Officer c/- Eli Lilly Australia Pty Ltd, 112 Wharf Road, Melrose Park NSW 2114.

For more information on how Lilly handles personal information, please see our Privacy Policy at https://www.lillyprivacy.com/au-en/hcp

Israel

Welcome to a website of Eli Lilly and Company Limited ("Lilly"). By using this website (also referred to herein as the 'site'), you agree to be bound by the following terms and all applicable laws and regulations. Your use of this site is also subject to the Privacy and Cookie Policy and Copyright Statement

Disclaimer

This site and the content are provided "as is". Lilly, its licensors, and its suppliers, to the fullest extent permitted by law, disclaim any and all warranties, whether express or implied, statutory or otherwise. Specifically, Lilly, its licensors, and its suppliers make no representations or warranties about the accuracy, reliability, completeness, currentness, suitability or timeliness of the content, software, text, graphics, tools, links, or communications provided on or through the use of the website or Lilly, or on any site or sites "linked" to this site. Lilly makes no warranty that the site will be available, uninterrupted, error free, or free of viruses or other harmful components.

To the fullest extent permitted by applicable law, in no event shall Lilly, its licensors, its suppliers, or any third parties mentioned on the website be liable for any damages or expenses of any kind (including, without limitation, compensatory, direct, indirect, incidental or consequential damages, loss of income or profits, or damages resulting from lost data or business interruption, loss of or damage to property or claims by third parties howsoever arising in connection with your use of this website) resulting from the use or inability to use the website or the content or any failure of performance, error, omission, interruption, effect, delay in operation or transmission, computer virus, line system failure, loss of data, or loss of use related to the site or any web site operated by any third party, whether based on contract, tort, or any other legal theory, and whether or not Lilly is advised of the possibility of such damages. To discontinue use of the site is your sole and exclusive remedy.

The content of the website in no way is intended to be a substitute for professional medical advice and should not be interpreted as treatment recommendations. Neither the content nor any other service offered by or through this website is intended to be relied on for medical diagnosis or treatment. Always seek the advice of a health care professional with any questions you may have regarding a medical condition.

Links

As a resource to our visitors, this site provides links to other web sites. However, because Lilly does not control the content of the other websites it may link to, and due to their constantly changing nature, Lilly is not responsible for the content, practices or standards of third-party sites. Lilly does not endorse the content on any third-party websites. Lilly is not responsible for the content of linked third-party sites, sites framed within the site, or third- party advertisements, and does not make any representations regarding their content or accuracy. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Use and Disclosure of Information

Except as expressly set forth on the site, if you submit any information to us, including any comments, remarks, suggestions, ideas, notes, drawings, graphics, concepts, or other information, you are giving that information, and all your rights in it, to Lilly free of charge and such information shall be deemed to be non-confidential and Lilly shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose and distribute the information to others without limitation other than the ones established by the Data Protection Act 1998 and any relevant privacy law or regulation, without your consent or any compensation to you or anyone else. Lilly shall be free to use any know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information.

This is true whether you submit such information to us by e-mail, through a form on the site, on a bulletnboard, or in any other manner. Lilly may from time to time monitor, review and, in its sole discretion, modify or delete any postings you make on the site however, Lilly is not obligated to do so.

20230704322 93

Using the Site/Security

You agree not to submit or transmit any material that is unlawful, threatening, libellous, defamatory, obscene, pornographic, profane, or might in any other way violate any law, regulation, or rule. You are solely responsible for any material you submit to the site. You further agree not to upload, email, post or transmit to, or distribute or otherwise publish through the site any material which disrupts the normal operation of the site, including posting or otherwise transmitting material that is not related to the subject at issue or otherwise restricts or inhibits any other user from using the site.

To obtain full access to the site, you may be required to complete a registration. You are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer. You accept responsibility for all activities that occur under your account or password and such use shall be deemed to be use by you. You will ensure that all use of your account fully complies with these Terms of Use. Transfer of the account by you to any other person or entity is prohibited.

When using the site, information will be transmitted over a medium that is beyond the control and jurisdiction of Lilly and its suppliers. Accordingly, Lilly assumes no liability for or relating to the delay, failure, interruption, or corruption of any data or other information transmitted in connection with use of this site.

Restrictions

Lilly is located in Israel. This site is intended for the exclusive use of residents of Israel. Lilly makes no representation that the materials on the site are appropriate or available for use in other locations. Access to the content may not be legal by certain persons or in certain countries outside of Israel. If you access this site from outside of Israel, you do so at your own risk and are responsible for compliance with the laws of your jurisdiction. This site is not intended for or designed to attract individuals who are minors under the age of 18 years.

Disputes and Applicable Law

These Terms of Use and any dispute or claim arising out of or in connection with it or its subject matter or formation (including any non-contractual disputes or claims) are governed by the internal substantive laws of Israel, without resort to its conflict of laws principles. If any provision of these Terms of Use is found to be invalid by any court having competent jurisdiction, the invalidity of such provision shall not affect the validity of the remaining provisions of these Terms of Use. You expressly agree that the Courts of Tel Aviv-Jaffa shall have exclusive jurisdiction to settle any dispute or claim with Lilly, or any dispute or claim relating to or arising out of your use of this site or any dispute or claim arising out of or in connection with these Terms of Use, their subject matter or formation (including non-contractual disputes or claims).

Entire Agreement

Except as expressly provided in a particular "legal notice" on this site, these Terms of Use, the Copyright Statement and the Privacy and Cookie Policy constitute the entire agreement between you and Lilly with respect to the use of this site, and content.

Changes to Terms of Use

Lilly may modify these Terms of Use at any time without notice to you. Lilly may terminate these Terms of Use, terminate your access to all or part of the site, or suspend any user's access to all or part of the site, at any time, without notice to you, if it believes, in its sole judgment, that you have breached or may breach any term or condition of these Terms of Use, or for its convenience. You may terminate this agreement at any time by destroying all materials received from the site and ceasing to use the site.

Accessibility Statement

Eli Lilly and Company is committed to creating websites that are easy to use and easy to get to for all people, regardless of ability or technology. If you are experiencing difficulty viewing or navigating the content on this website, or you believe that certain content is not fully accessible, please contact us and provide a description of the specific feature you feel is not fully accessible or

20230704322941

with suggestions for improvement. Your feedback is important to us, and we will take it under consideration and handle the matter as soon as possible.

Copyrights:

Everything that you read or see on the site is copyrighted or otherwise protected and owned by Eli Lilly and Company ('Lilly') or by a third party who licensed or granted to Lilly the right to use such material. Unless otherwise expressly noted, nothing that you read or see on the site may be copied or used except as provided in the Terms of Use or with the prior written approval of Lilly.

We grant you permission to print individual pages from the site, unless otherwise expressly noted, for your own personal, non-commercial use in learning about the services or products offered by Lilly or for your non-commercial use in connection with healthcare or education. If you are a health care professional or provider, you may print individual pages from the site, unless otherwise expressly noted, and share the information and materials with others. No other permission is granted to you to license, sale, store, alter, modify, or create derivative works of these materials. This grant of permission is not a transfer of title, and under this permission you may not:

• Use the materials for any commercial purpose, or for any public display;

• Remove any copyright, trademark or other proprietary notations from the materials;

• "mirror" the materials on any other server.

We make no warranties or representations to you that your use of any materials displayed on the site will not infringe the rights of third parties.

Unless otherwise indicated, all logos, names, designs, and marks on the site are trademarks owned or used under license by Lilly. The use or misuse of any of these marks or other information is strictly prohibited. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark or other intellectual property right of Lilly or any third party. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Lilly copyright.

Electronic Record and Signature Disclosure created on: 12/27/2021 8:31:17 AM
Parties agreed to: Daniel Lucas

UK

Ireland

South Africa

Australia & New Zealand

Israel

United Kingdom

Terms of use

In order to provide You with certain services as part of the relationship between You and Eli Lilly and Company or any of its subsidiaries (hereinafter, we, us or Lilly), particularly the electronic signature for contracted services, Lilly has engaged DocuSign Inc to manage electronic signature, based on an email procedure.

To that effect, Lilly might share with DocuSign, acting as data processor for Lilly, certain data as your email address, in order to allow tracking of the documents being signed and reminders or to provide to you certain written notices electronically. Any data to be disclosed by Lilly and/or captured by DocuSign is to support and facilitate the signing of the contract.

To use this service it is not compulsory upon You to create a DocuSign User account. If You voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following Lilly_UK_CMS@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Please, be aware that if you elect not to use the electronic signature service and electronic communications, it will slow the speed at which we can complete certain steps in transactions with You.

Your privacy is important to us. This Privacy Statement explains how Eli Lilly and Company (Lilly) collects personal data about you, why we collect it, and with whom we may share it. It also explains your rights with regard to this personal data. This Privacy Statement applies to all

20230704322295

personal data about you, regardless of whether the information is stored electronically or in hard copy.

Information We Collect and How We Use It

Your personal information, including your name, electronic signature and IP address will be used by Lilly or third parties acting on our behalf, for the purpose of creating and processing your contracts with Lilly. We may also use the information to meet legal or regulatory obligations, inclusive of company record retention that are in the legitimate interest of Lilly.

Your information may be combined with information from other public sources or other interactions we have with you.

To use this service it is not compulsory upon you to create a DocuSign User account. If you voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_uk_cms@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Processing operations may include the recording, organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction of personal data.

Reasons We Share Your Information

We may share your personal information with other Lilly affiliates and its agents and vendors worldwide for purposes consistent with those identified in this notice. All third parties that have access to your information have agreed to protect the information and to use it only as directed by us.

We may also be required to disclose your information in response to lawful requests by public authorities, including to comply with national security or law enforcement requests.

Where We Store and Process Your Information

We may transmit personal information about you to other Lilly affiliates worldwide. These affiliates may in turn transmit personal information about you to other Lilly affiliates. Some of Lilly's affiliates may be located in countries that do not ensure an adequate level of data protection. Nevertheless, all of Lilly's affiliates are required to treat personal information in a manner consistent with this notice. To obtain additional information regarding the basis for transfers and safeguards that Lilly has in place for cross-border transfers of personal information, please contact us at privacy@lilly.com or visit https://www.lilly.com/privacy.

How Long We Keep Your Information

Your information will be saved for a period of time needed to fulfill legitimate and lawful business purposes in accordance with Lilly's records retention policies and applicable laws and regulations.

How We Secure Your Information

We provide reasonable physical, electronic, and procedural safeguards to protect information we process and maintain. We limit access to your information to authorized employees, agents, contractors, vendors, subsidiaries, and business partners, or others who need such access to information to carry out their assigned roles and responsibilities on behalf of Lilly. Please be aware, although we try to protect the information we process and maintain, no security system can prevent all potential security breaches.

Your Rights and Choices

You have the right to request information from us on how your personal information is being used and with whom that information is being shared. You also have the right to request to see and get a copy of the personal information that we have about you, request its correction or request its erasure.

You also have the right to have your information transmitted to another entity or person in a machine-readable format, in limited circumstances. There may be limitations on our ability to comply with your request.

20230704322961

You, as a signee and/or authorized user of the DocuSign system may have access to and print a copy of any record provided or made available electronically to you by Lilly through DocuSign, by any of these means

- You can access the documents via the link originally provided in the email;
- You may contact our Customer Meetings Services via telephone at the following number: 020 3684 0772 - Selecting option 2 or
- If you have voluntarily created a DocuSign user account, you can login and see all documents sent to the email address connected with that account. Such account would be between You and DocuSign and not connected to Lilly; therefore Lilly would not take any responsibility for this and all legal notices applying are those of DocuSign.

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at lilly_uk_cms@lilly.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address.

In addition, if you have created a DocuSign user account you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

How to Contact Us

You may make any of the above requests by contacting us at:
Eli Lilly and Company Limited
Lilly House,
Priestley Road,
Basingstoke,
Hampshire,
RG24 9NL
Tel: 020 3684 0772 - Selecting option 2

How to Submit a Complaint

If you wish to raise a complaint on how we have handled your personal information, you can contact our Data Protection Officer at privacy@lilly.com who will investigate the matter.

If you are not satisfied with our response or believe we are processing your personal information not in accordance with the law you can register a complaint with a Data Protection Authority (DPA).

Ireland

Terms of use

In order to provide You with certain services as part of the relationship between You and Eli Lilly and Company or any of its subsidiaries (hereinafter, we, us or Lilly), particularly the electronic signature for contracted services, Lilly has engaged DocuSign Inc to manage electronic signature, based on an email procedure.

To that effect, Lilly might share with DocuSign, acting as data processor for Lilly, certain data as your email address, in order to allow tracking of the documents being signed and reminders or to provide to you certain written notices electronically. Any data to be disclosed by Lilly and/or captured by DocuSign is to support and facilitate the signing of the contract.

To use this service it is not compulsory upon You to create a DocuSign User account. If You voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_ireland_cms@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Please, be aware that if you elect not to use the electronic signature service and electronic communications, it will slow the speed at which we can complete certain steps in transactions with You.

Your privacy is important to us. This Privacy Statement explains how Eli Lilly and Company (Lilly) collects personal data about you, why we collect it, and with whom we may share it. It also explains your rights with regard to this personal data. This Privacy Statement applies to all personal data about you, regardless of whether the information is stored electronically or in hard copy.

Information We Collect and How We Use It

Your personal information, including your name, electronic signature and IP address will be used by Lilly or third parties acting on our behalf, for the purpose of creating and processing your

20230702432297

contracts with Lilly. We may also use the information to meet legal or regulatory obligations, *inclusive of company record retention that are in the legitimate interest of Lilly.*

Your information may be combined with information from other public sources or other interactions we have with you.

To use this service it is not compulsory upon you to create a DocuSign User account. If you voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_ireland_cms@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Processing operations may include the recording, organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction of personal data.

Reasons We Share Your Information

We may share your personal information with other Lilly affiliates and its agents and vendors worldwide for purposes consistent with those identified in this notice. All third parties that have access to your information have agreed to protect the information and to use it only as directed by us.

We may also be required to disclose your information in response to lawful requests by public authorities, including to comply with national security or law enforcement requests.

Where We Store and Process Your Information

We may transmit personal information about you to other Lilly affiliates worldwide. These affiliates may in turn transmit personal information about you to other Lilly affiliates. Some of Lilly's affiliates may be located in countries that do not ensure an adequate level of data protection. Nevertheless, all of Lilly's affiliates are required to treat personal information in a manner consistent with this notice. To obtain additional information regarding the basis for transfers and safeguards that Lilly has in place for cross-border transfers of personal information, please contact us at privacy@lilly.com or visit https://www.lilly.com/privacy.

How Long We Keep Your Information

Your information will be saved for a period of time needed to fulfill legitimate and lawful business purposes in accordance with Lilly's records retention policies and applicable laws and regulations.

How We Secure Your Information

We provide reasonable physical, electronic, and procedural safeguards to protect information we process and maintain. We limit access to your information to authorized employees, agents, contractors, vendors, subsidiaries, and business partners, or others who need such access to information to carry out their assigned roles and responsibilities on behalf of Lilly. Please be aware, although we try to protect the information we process and maintain, no security system can prevent all potential security breaches.

Your Rights and Choices

You have the right to request information from us on how your personal information is being used and with whom that information is being shared. You also have the right to request to see and get a copy of the personal information that we have about you, request its correction or request its erasure.

You also have the right to have your information transmitted to another entity or person in a machine-readable format, in limited circumstances. There may be limitations on our ability to comply with your request.

You, as a signee and/or authorized user of the DocuSign system may have access to and print a copy of any record provided or made available electronically to you by Lilly through DocuSign, by any of these means:

- You can access the documents via the link originally provided in the email;
- You may contact our Customer Meetings Services via telephone at the following number: 020 3684 0772 - Selecting option 2 or
- If you have voluntarily created a DocuSign user account, you can login and see all documents sent to the email address connected with that account. Such account would be between You and DocuSign and not connected to Lilly; therefore Lilly would not take any responsibility for this and all legal notices applying are those of DocuSign.

20230704322 98

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at lilly_ireland_cms@lilly.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address.

In addition, if you have created a DocuSign user account you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

How to Contact Us

You may make any of the above requests by contacting us at:
Eli Lilly and Company Limited
Lilly House,
Priestley Road,
Basingstoke,
Hampshire,
RG24 9NL
Tel: 020 3684 0772 - Selecting option 2

How to Submit a Complaint

If you wish to raise a complaint on how we have handled your personal information, you can contact our Data Protection Officer at privacy@lilly.com who will investigate the matter.

If you are not satisfied with our response or believe we are processing your personal information not in accordance with the law you can register a complaint with a Data Protection Authority (DPA).

South Africa

Agreement to do business with Eli Lilly and Company

USER NOTICE

- Terms of use
- Access to Document history by You
- Changes of e-mail address
- Privacy statement
- Required hardware and software

Terms of use

In order to provide You with certain services as part of the relationship between You and Eli Lilly and Company or any of its subsidiaries (hereinafter, we, us or Lilly), particularly the electronic signature for contracted services, Lilly has engaged DocuSign Inc to manage electronic signature, based on an email procedure.

To that effect, Lilly might share with DocuSign, acting as data processor for Lilly, certain data as your email address, in order to allow tracking of the documents being signed and reminders or to provide to you certain written notices electronically. Any data to be disclosed by Lilly and/or captured by DocuSign is to support and facilitate the signing of the contract.

To use this service it is not compulsory upon you to create a DocuSign User account. If you voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following Lilly_southafrica_CMS@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Please, be aware that if you elect not to use the electronic signature service and electronic communications, it will slow the speed at which we can complete certain steps in transactions with you.

Access to Document history by you

You, as a signee and/or authorized user of the DocuSign system may have access to and print a copy of any record provided or made available electronically to you by Lilly through DocuSign, by any of these means:

20230704032299

- You can access the documents via the link originally provided in the email;
- You may contact our Customer Meetings Services via email lilly_southafrica_CMS@lilly.com; or
- If you have voluntarily created a DocuSign user account, you can login and see all documents sent to the email address connected with that account. Such account would be between you and DocuSign and not connected to Lilly; therefore, Lilly would not take any responsibility for this and all legal notices applying are those of DocuSign.

Changes of e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at Lilly_southafrica_CMS@lilly.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address.

In addition, if you have created a DocuSign user account you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

Privacy Statement

Your privacy is important to us. This Privacy Statement is intended to let you know what information Eli Lilly South Africa may collect about you and how we use that information. This Privacy Statement applies to websites that link to this statement when you click on "Privacy Statement" in the website footer, as well as mobile applications and digital services that link to or post this Privacy Statement. In this Privacy Statement, we will refer to the websites, Apps, and Digital Services that may link to or post this Privacy Statement as “websites.”

Information We Collect and How We Use It

- Summary. This website may collect Personal Information that either directly identifies you or could be used in combination with other information to identify you. Examples of Personal Information that directly identify you include your name, contact information, email address, and other information in combination with identifiers. Our websites may also collect Personal Information that does not directly identify you by name or contact information but which may be used to identify that a specific computer or device has accessed our website.

Through this website we may collect the following information about you:

- Contact information. This might include information such as your name, address, telephone number, e-mail address, and other similar information ("Personal Information"). We collect this information so that we can communicate with you. You may always refuse to provide Personal Information to us, but then we may not be able to provide you with certain information, products, or services.
- Additional Information. Certain areas of our Websites allow you to share additional Personal Information with us. For example, you may subscribe to one of our mailing lists or newsletters. We may use the information you provide to send your requested information, respond to your inquiry, improve our websites, verify your relationship with us, and take other actions that may be necessary to respond to your request.
- Interests and preferences. This information lets us better understand how to best serve you based on your interest in our products and services. This information may include your preferences about how to contact you, further develop a business or professional relationship, understand product preferences, languages, marketing preferences and some demographic data. Some of this information we collect with your consent and some of this information we collect automatically for our legitimate business purposes.
- Website Usage. We use this information to manage and secure our websites, network systems and other assets. This may include information about your IP ("Internet Protocol") address, the date and time of your website session, geographic location, and how you have navigated the website, and other information collected through our weblogs, cookies or in other ways. This may also include information that does not directly identify you but which corresponds to your device. It is possible that your IP Address, or a cookie that we use, may contain information that may be considered Personal Information. How we use Cookies and other technologies is described in more detail below. This information is collected automatically, for our legitimate business purposes.

We may also use the information to meet legal or regulatory obligations, such as adverse event reporting or to enforce our rights; and for company record retention, website management, research and product development that are in the legitimate interest of Lilly.

Where permitted by law, we may also enhance or merge information about you, including Personal Information, with information about you obtained from third parties for the same purposes shared above. Your information may also be used for profiling for the same purposes shared above. You may object to profiling via automated-decision making by contacting us using the information in the "How to Contact Us" section below.

Cookies and Similar Technologies

Web beacons

20230704323OO

This site may use a technology known as web beacons that allows the collection of web log information. A web beacon is a tiny graphic on a web page or in an e-mail message designed to track pages viewed or messages opened. Web log information is gathered when you visit one of our websites by the computer that hosts our website (called a "webserver").

On certain web pages or in emails we send to you, we may utilize a technology called a “web beacon” (also known as an “action tag” or “clear GIF technology”). We may use web beacons to help determine which email messages sent by us were opened and whether a message was acted upon. Web beacons also help analyze the effectiveness of websites by measuring the number of visitors to a site or how many visitors clicked on key elements of a site.

Cookies

This website may use a technology called a "cookie". A cookie is a small data file that a website can place on your computer’s hard drive, where your internet browser files are kept. A cookie saves you the trouble of reentering certain information in some registration areas because cookies can be used to enable a site to “remember” information a visitor has previously inputted. A cookie also helps deliver content used -specific information to you and track how sections of the website are used. Cookies can be placed on your computer both by us and by third parties with whom we have a relationship, such as web analytic services and advertising network services. With most Internet browsers or other software, you can change your browser settings to erase cookies from your computer hard drive, block all cookies or receive a warning before a cookie is stored. Please check your browser instructions to learn more about these functions. If you reject cookies, functionality of the site may be limited, and you may not be able to take advantage of many of the site's features.

Do Not Track

There are different ways you can prevent tracking of your online activity. One of them is setting a preference in your browser that alerts websites you visit that you do not want them to collect certain information about you. This is referred to as a Do-Not-Track (“DNT”) signal. Please note that currently our websites and web-based resources do not respond to these signals from web browsers. At this time, there is no universally accepted standard for what a company should do when a DNT signal is detected.

Reasons Your Information is Shared

We may share your Personal Information with our agents, contractors or partners in connection with work that they do for, or with, Lilly, such as sending email messages, managing data, hosting our databases, providing data processing services, providing customer service, or so we may enhance or add data about you from these other entities. These agents, contractors or partners are restricted from using this data in any way other than to provide services for us, or services for the collaboration in which they are engaged with us (for example, some of our products are developed and marketed through joint agreements with other companies).

We will share Personal Information to respond to subpoenas or other lawful information requests of governmental authorities, including to meet national security or law enforcement requirements, to provide Internet security, or where required by law. In exceptionally rare circumstances where national, state or company security is at issue, we reserves the right to share our entire database of visitors and customers with appropriate governmental authorities.

We may also provide your Personal Information to a third party in connection with the sale, assignment, or other transfer of the business of a website to which the information relates, in which case we will require any such buyer to agree to treat Personal Information in accordance with this Privacy Statement.

Google Analytics

Google Analytics may be used to help make our website work better and to help us understand what parts of the website are being utilized. Google Analytics uses technical tools such as, First-party cookies and JavaScript code, to collect information about visitors. Google Analytics service tracks visitors to the site who have JavaScript enabled. Google Analytics anonymously tracks how visitors interact with a website, including where they came from and what they did on a site. Google Analytics collects the information set forth above from users.

This information is used to administer and update the website, and we will also assess whether the visitors to the site match the expected site demographics and determine how key audiences are navigating the content.

First-party cookies (such as the Google Analytics cookie) and third-party cookies (such as the DoubleClick cookie) will be used to report how your ad impressions, other uses of ad services, and interactions with these ad impressions and ad services are related to visits to this site.

A. Opt-Out Provision:
   Google analytics offers an opt-out provision for website visitors who do not want their data to be collected. You can receive more information about this option here:http://tools.google.com/dlpage/gaoptout
B. Google's Use of Data:
   Google and its wholly owned subsidiaries may retain and use, subject to the terms of its Privacy Policy (located at http://www.google.com/privacy.html, or such other URL as Google may provide from time to time), information collected in your use of the Google Analytics Information Disclosures and Sharing.
C.
D.

Social Media Plugins

Our websites may use Social Media Plugins to enable you to easily share information with others. When you visit our websites, the operator of the social media plugin that is

20230704323O1

on our website can place a cookie on your computer that lets that operator to recognize individuals on their website who have previously visited our sites. If you have previously logged into the social media website while browsing on our website, social media plugins may allow that social media website to receive directly identifiable information about you that shows you have visited our website. The social media plugin may collect this information for visitors who have logged into social networks, whether or not they specifically interact with the plugin on our website. Social media plugins also allow the social media website to share information about your activities on our website with other users of their social media website. Lilly does not control any of the content from social media plugins. For more information about social plugins from social media websites you should refer to those sites' privacy and data sharing statements.

How Long We Keep Your Information

Your Information will be saved for a period of time needed to fulfill legitimate and lawful business purposes in accordance with our records retention policies and applicable laws and regulations.

Children's Information

This site is not intended for or designed for individuals under the age of 18. We do not knowingly collect Personal Information from any person under the age of 18.

How We Secure Your Information

We provide reasonable physical, electronic, and procedural safeguards to protect Personal Information collected via this website. For example, we limit access to this information to authorized employees, service providers, and contractors who need access to perform the activities described in this notice. Although we strive to provide reasonable security for information we process and maintain, no security system can prevent all potential security breaches.

Your Rights and Choices

You have the right to request information from us on how your personal information is being used and with whom that information is being shared. You also have the right to

see and get a copy of the personal information that we have about you. If you believe any of this information to be inaccurate or incomplete, you have the right to request its correction or erasure.

There may be limitation on our ability to comply with your request.

How to Contact Us

You may make any of the above requests by contacting us at:
ELI LILLY (S.A.) (PTY) LTD
First Floor, Golden Oak House, BallyOaks Office Park, 35 Ballyclare Drive, Bryanston, South Africa, 2191
+27 11 510 9370
privacy_za@lilly.com

You may also contact us at the above if you have questions about this Privacy Statement.

How to Submit a Complaint

If you wish to raise a complaint on how we have handled your personal information, you can contact us at:
ELI LILLY (S.A.) (PTY) LTD
First Floor, Golden Oak House, BallyOaks Office Park, 35 Ballyclare Drive, Bryanston, South Africa, 2191
+27 11 510 9370
privacy_za@lilly.com

If you are not satisfied with our response or believe we are processing your personal information not in accordance with the law you can register a complaint with a Data Protection Authority (DPA).

Links to Third Party Websites

As a convenience to our visitors, this Website may contain links to other sites owned and operated by third parties that we believe may offer useful information. The policies and procedures we describe here do not apply to those sites. We are not responsible for the collection or use of Personal Information at any third party sites. Therefore, we disclaim any liability for any third party's use of Personal Information obtained through using the

20230704323O2

third party web site. We suggest contacting those sites directly for information on their privacy, security, data collection, and distribution policies.

Transfer of Personal Information Internationally

Lilly may transmit personal information about you to other Lilly affiliates worldwide. These affiliates may in turn transmit personal information about you to other Lilly affiliates. Some of Lilly's affiliates may be located in countries that do not ensure an adequate level of data protection. Nevertheless, all of Lilly's affiliates are required to treat personal information in a manner consistent with this notice.

Changes to Our Privacy Practices

We may update this Privacy Statement from time to time. When we do update it, for your convenience, we will make the updated statement available on this page. We will always handle your Personal Information in accordance with the Privacy Statement in effect at the time it was collected. We will not make any materially different use or new disclosure of your Personal Information to another entity using your Personal Information for its own purposes unless we notify you and give you an opportunity to object.

Last Updated: 14th February 2020

For more information about how Lilly companies in the U.S. process the personal information originating from South Africa, see the Lilly Privacy Notice available above

Your data will be kept for at least as long as the contract is retained. You have the right to review and correct, where needed, your personal information.

If you have questions about the information we process about you, please contact: Lilly_southafrica_CMS@lilly.com

Australia & New Zealand

Agreement to do business with Eli Lilly and Company

USER NOTICE

- Terms of use
- Access to Document history by You
- Changes of e-mail address
- Privacy statement
- Required hardware and software

Terms of use

In order to provide You with certain services as part of the relationship between You and Eli Lilly and Company or any of its subsidiaries (hereinafter, we, us or Lilly), particularly the electronic signature for contracted services, Lilly has engaged DocuSign Inc to manage electronic signatures, based on an email procedure.

To that effect, Lilly might share with DocuSign, acting as data processor for Lilly, certain data such as your email address, in order to allow tracking of the documents being signed and reminders or to provide to you certain written notices electronically. Any data to be disclosed by Lilly and/or captured by DocuSign is to support and facilitate the signing of documents.

To use this service, it is not compulsory that you create a DocuSign User account. If you voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no liability or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_anz_cms@lilly.com. Additionally, if you have created a DocuSign User account, to withdraw your consent you must use the DocuSign "Withdraw Consent" form on the signing page of your DocuSign User account. Lilly has no responsibility in that regard.

Please, be aware that if you elect not to use the electronic signature service and electronic communications, it will slow the speed at which we can complete certain steps in transactions with you.

Access to Document history by you

20230704323O3

You, as a signee and/or authorized user of the DocuSign system may have access to and print a copy of any record provided or made available electronically to you by Lilly through DocuSign, by any of these means:

- You can access the documents via the link originally provided in the email;
- You may contact our Customer Meetings Services via email at lilly_anz_cms@lilly.com; or
- If you have voluntarily created a DocuSign User account, you can login and see all documents sent to the email address connected with your User account. Your account is between you and DocuSign and not connected to Lilly; therefore, Lilly takes no responsibility for your User account and all legal notices applying are those of DocuSign.

Changes of e-mail address

To let Lilly know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at lilly_anz_cms@lilly.com and in the body of such request please state: your previous e-mail address, your new e-mail address. Alternatively, you can update your contact information via the WebServices Portal.

If you have created a DocuSign User account you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign User account by following the process for changing e-mail in DocuSign.

Privacy Statement

As indicated at the beginning of this notice, for the purpose of facilitating electronically signing documents, we will capture some personal information like name, email address, IP address, a series of dates (sent/viewed/signed), whether you signed using the DocuSign mobile app or not and an image of the signature used.

Your personal information will be retained by Lilly and, in accordance with the purposes set out above, some personal information may be disclosed to other Lilly affiliates, (located outside Australia, including Eli Lilly and Company located at Indianapolis, Indiana, U.S.A.), to selected third party service providers and as required by law or industry codes of conduct. U.S. or other foreign government agencies may be able to obtain access to your personal information under

applicable law. For questions about the collection, use of disclosure of personal information, to request access, correction or deletion of personal information held by Lilly about the HCP, or to make a complaint about the handling of personal information, contact Lilly's Privacy Officer c/- Eli Lilly Australia Pty Ltd, 112 Wharf Road, Melrose Park NSW 2114.

For more information on how Lilly handles personal information, please see our Privacy Policy at https://www.lillyprivacy.com/au-en/hcp

Israel

Welcome to a website of Eli Lilly and Company Limited ("Lilly"). By using this website (also referred to herein as the 'site'), you agree to be bound by the following terms and all applicable laws and regulations. Your use of this site is also subject to the Privacy and Cookie Policy and Copyright Statement

Disclaimer

This site and the content are provided "as is". Lilly, its licensors, and its suppliers, to the fullest extent permitted by law, disclaim any and all warranties, whether express or implied, statutory or otherwise. Specifically, Lilly, its licensors, and its suppliers make no representations or warranties about the accuracy, reliability, completeness, currentness, suitability or timeliness of the content, software, text, graphics, tools, links, or communications provided on or through the use of the website or Lilly, or on any site or sites "linked" to this site. Lilly makes no warranty that the site will be available, uninterrupted, error free, or free of viruses or other harmful components.

To the fullest extent permitted by applicable law, in no event shall Lilly, its licensors, its suppliers, or any third parties mentioned on the website be liable for any damages or expenses of any kind (including, without limitation, compensatory, direct, indirect, incidental or consequential damages, loss of income or profits, or damages resulting from lost data or business interruption, loss of or damage to property or claims by third parties howsoever arising in connection with your use of this website) resulting from the use or inability to use the website or the content or any failure of performance, error, omission, interruption, effect, delay in operation or transmission, computer virus, line system failure, loss of data, or loss of use related to the site or any web site operated by any third party, whether based on contract, tort, or any other legal theory, and whether or not Lilly is advised of the possibility of such damages. To discontinue use of the site is your sole and exclusive remedy.

20230704323304

The content of the website in no way is intended to be a substitute for professional medical advice and should not be interpreted as treatment recommendations. Neither the content nor any other service offered by or through this website is intended to be relied on for medical diagnosis or treatment. Always seek the advice of a health care professional with any questions you may have regarding a medical condition.

Links

As a resource to our visitors, this site provides links to other web sites. However, because Lilly does not control the content of the other websites it may link to, and due to their constantly changing nature, Lilly is not responsible for the content, practices or standards of third-party sites. Lilly does not endorse the content on any third-party websites. Lilly is not responsible for the content of linked third-party sites, sites framed within the site, or third- party advertisements, and does not make any representations regarding their content or accuracy. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Use and Disclosure of Information

Except as expressly set forth on the site, if you submit any information to us, including any comments, remarks, suggestions, ideas, notes, drawings, graphics, concepts, or other information, you are giving that information, and all your rights in it, to Lilly free of charge and such information shall be deemed to be non-confidential and Lilly shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose and distribute the information to others without limitation other than the ones established by the Data Protection Act 1998 and any relevant privacy law or regulation, without your consent or any compensation to you or anyone else. Lilly shall be free to use any know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information.

This is true whether you submit such information to us by e-mail, through a form on the site, on a bulletnboard, or in any other manner. Lilly may from time to time monitor, review and, in its sole discretion, modify or delete any postings you make on the site however, Lilly is not obligated to do so.

Using the Site/Security

You agree not to submit or transmit any material that is unlawful, threatening, libellous, defamatory, obscene, pornographic, profane, or might in any other way violate any law, regulation, or rule. You are solely responsible for any material you submit to the site. You further agree not to upload, email, post or transmit to, or distribute or otherwise publish through the site any material which disrupts the normal operation of the site, including posting or otherwise transmitting material that is not related to the subject at issue or otherwise restricts or inhibits any other user from using the site.

To obtain full access to the site, you may be required to complete a registration. You are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer. You accept responsibility for all activities that occur under your account or password and such use shall be deemed to be use by you. You will ensure that all use of your account fully complies with these Terms of Use. Transfer of the account by you to any other person or entity is prohibited.

When using the site, information will be transmitted over a medium that is beyond the control and jurisdiction of Lilly and its suppliers. Accordingly, Lilly assumes no liability for or relating to the delay, failure, interruption, or corruption of any data or other information transmitted in connection with use of this site.

Restrictions

Lilly is located in Israel. This site is intended for the exclusive use of residents of Israel. Lilly makes no representation that the materials on the site are appropriate or available for use in other locations. Access to the content may not be legal by certain persons or in certain countries outside of Israel. If you access this site from outside of Israel, you do so at your own risk and are responsible for compliance with the laws of your jurisdiction. This site is not intended for or designed to attract individuals who are minors under the age of 18 years.

Disputes and Applicable Law

20230704323305

These Terms of Use and any dispute or claim arising out of or in connection with it or its subject matter or formation (including any non-contractual disputes or claims) are governed by the internal substantive laws of Israel, without resort to its conflict of laws principles. If any provision of these Terms of Use is found to be invalid by any court having competent jurisdiction, the invalidity of such provision shall not affect the validity of the remaining provisions of these Terms of Use. You expressly agree that the Courts of Tel Aviv-Jaffa shall have exclusive jurisdiction to settle any dispute or claim with Lilly, or any dispute or claim relating to or arising out of your use of this site or any dispute or claim arising out of or in connection with these Terms of Use, their subject matter or formation (including non-contractual disputes or claims).

Entire Agreement

Except as expressly provided in a particular "legal notice" on this site, these Terms of Use, the Copyright Statement and the Privacy and Cookie Policy constitute the entire agreement between you and Lilly with respect to the use of this site, and content.

Changes to Terms of Use

Lilly may modify these Terms of Use at any time without notice to you. Lilly may terminate these Terms of Use, terminate your access to all or part of the site, or suspend any user's access to all or part of the site, at any time, without notice to you, if it believes, in its sole judgment, that you have breached or may breach any term or condition of these Terms of Use, or for its convenience. You may terminate this agreement at any time by destroying all materials received from the site and ceasing to use the site.

Accessibility Statement

Eli Lilly and Company is committed to creating websites that are easy to use and easy to get to for all people, regardless of ability or technology. If you are experiencing difficulty viewing or navigating the content on this website, or you believe that certain content is not fully accessible, please contact us and provide a description of the specific feature you feel is not fully accessible or

with suggestions for improvement. Your feedback is important to us, and we will take it under consideration and handle the matter as soon as possible.

Copyrights:

Everything that you read or see on the site is copyrighted or otherwise protected and owned by Eli Lilly and Company ('Lilly') or by a third party who licensed or granted to Lilly the right to use such material. Unless otherwise expressly noted, nothing that you read or see on the site may be copied or used except as provided in the Terms of Use or with the prior written approval of Lilly.

We grant you permission to print individual pages from the site, unless otherwise expressly noted, for your own personal, non-commercial use in learning about the services or products offered by Lilly or for your non-commercial use in connection with healthcare or education. If you are a health care professional or provider, you may print individual pages from the site, unless otherwise expressly noted, and share the information and materials with others. No other permission is granted to you to license, sale, store, alter, modify, or create derivative works of these materials. This grant of permission is not a transfer of title, and under this permission you may not:

• Use the materials for any commercial purpose, or for any public display;

• Remove any copyright, trademark or other proprietary notations from the materials;

• "mirror" the materials on any other server.

We make no warranties or representations to you that your use of any materials displayed on the site will not infringe the rights of third parties.

Unless otherwise indicated, all logos, names, designs, and marks on the site are trademarks owned or used under license by Lilly. The use or misuse of any of these marks or other information is strictly prohibited. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark or other intellectual property right of Lilly or any third party. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Lilly copyright.

20230704323306

Terms of use

In order to provide You with certain services as part of the relationship between You and Eli Lilly and Company or any of its subsidiaries (hereinafter, we, us or Lilly), particularly the electronic signature for contracted services, Lilly has engaged DocuSign Inc to manage electronic signature, based on an email procedure.

To that effect, Lilly might share with DocuSign, acting as data processor for Lilly, certain data as your email address, in order to allow tracking of the documents being signed and reminders or to provide to you certain written notices electronically. Any data to be disclosed by Lilly and/or captured by DocuSign is to support and facilitate the signing of the contract.

To use this service it is not compulsory upon You to create a DocuSign User account. If You voluntarily decide to create such an account, the terms and conditions, privacy notice, etc. applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_sverige_cms@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Please, be aware that if you elect not to use the electronic signature service and electronic communications, it will slow the speed at which we can complete certain steps in transactions with You.

Your privacy is important to us. This Privacy Statement explains how Eli Lilly and Company (Lilly) collects personal data about you, why we collect it, and with whom we may share it. It also explains your rights with regard to this personal data. This Privacy Statement applies to all personal data about you, regardless of whether the information is stored electronically or in hard copy.

Information We Collect and How We Use It
Your personal information, including your name, electronic signature and IP address will be used by Lilly or third parties acting on our behalf, for the purpose of creating and processing your contracts with Lilly. We may also use the information to meet legal or regulatory obligations, inclusive of company record retention that are in the legitimate interest of Lilly.

Your information may be combined with information from other public sources or other interactions we have with you.

To use this service it is not compulsory upon You to create a DocuSign User account. If You voluntarily decide to create such an account, the terms and conditions, privacy notice, etc.

applying will be those of DocuSign and Lilly will have no implication or responsibility with regard to such an account.

If you decide not to use the electronic signature service offered by Lilly and to receive electronic communications from Lilly and/or DocuSign, or you change your mind at any time, please contact our Customer Meetings Services via email at the following lilly_sverige_cms@lilly.com. Additionally, if you have created a DocuSign user account you would need to withdraw your consent using the DocuSign "Withdraw Consent" form on the signing page of your DocuSign account. Lilly has no responsibility in that regard.

Processing operations may include the recording, organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction of personal data.

Reasons We Share Your Information
We may share your personal information with other Lilly affiliates and its agents and vendors worldwide for purposes consistent with those identified in this notice. All third parties that have access to your information have agreed to protect the information and to use it only as directed by us. We may also be required to disclose your information in response to lawful requests by public authorities, including to comply with national security or law enforcement requests.

Where We Store and Process Your Information
We may transmit personal information about you to other Lilly affiliates worldwide. These affiliates may in turn transmit personal information about you to other Lilly affiliates. Some of Lilly's affiliates may be located in countries that do not ensure an adequate level of data protection. Nevertheless, all of Lilly's affiliates are required to treat personal information in a manner consistent with this notice. To obtain additional information regarding the basis for transfers and safeguards that Lilly has in place for cross-border transfers of personal information, please contact us at privacy@lilly.com or visit https://www.lilly.com/privacy

How Long We Keep Your Information
Your information will be saved for a period of time needed to fulfill legitimate and lawful business purposes in accordance with Lilly's records retention policies and applicable laws and regulations.

How We Secure Your Information
We provide reasonable physical, electronic, and procedural safeguards to protect information we process and maintain. We limit access to your information to authorized employees, agents, contractors, vendors, subsidiaries, and business partners, or others who need such access to information to carry out their assigned roles and responsibilities on behalf of Lilly. Please be aware, although we try to protect the information we process and maintain, no security system can prevent all potential security breaches.

Your Rights and Choices

202307043230?

You have the right to request information from us on how your personal information is being used and with whom that information is being shared. You also have the right to request to see and get a copy of the personal information that we have about you, request its correction or request its erasure.

You also have the right to have your information transmitted to another entity or person in a machine-readable format, in limited circumstances. There may be limitations on our ability to comply with your request.

You, as a signee and/or authorized user of the DocuSign system may have access to and print a copy of any record provided or made available electronically to you by Lilly through DocuSign, by any of these means:

- You can access the documents via the link originally provided in the email;
- You may contact our Customer Meetings Services via telephone at the following number 08-737 88 00; or
- If you have voluntarily created a DocuSign user account, you can login and see all documents sent to the email address connected with that account. Such account would be between You and DocuSign and not connected to Lilly; therefore Lilly would not take any responsibility for this and all legal notices applying are those of DocuSign.

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at lilly_sverige_cms@lilly.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address.

In addition, if you have created a DocuSign user account you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

How to Contact Us
You may make any of the above requests by contacting us at:

Lillys Data Privacy Steward i Sverige på telefon 08-737 88 00 eller på adressen Eli Lilly Sweden AB, Box 721, 169 27 Solna.

How to Submit a Complaint
If you wish to raise a complaint on how we have handled your personal information, you can contact our Data Protection Officer at privacy@lilly.com who will investigate the matter.

If you are not satisfied with our response or believe we are processing your personal information not in accordance with the law you can register a complaint with a Data Protection Authority (DPA).